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What this study adds: 
 A distribution of intervention impact across socioeconomic groups can be estimated from 
socioeconomic differences across a staircase using distributional cost effectiveness 
analysis (DCEA). 
 The extent to which evidence on inequality at different steps of the staircase contributes 
to uncertainty in population level impact is not well understood. 
 This study used two DCEAs to explore how socioeconomic inequality in model inputs 
impacts upon final conclusions about health inequality and value for money. 
 There was no discernible pattern relating the extent and direction of socioeconomic 
variation in model inputs to socioeconomic variation in model outputs. Differences in 
deprivation structure of the local population and other factors would translate into 
different conclusions on the value for money of delivering the interventions locally 
compared to nationally. 
 This study suggests there is limited scope for informally assessing the importance of lack 
of knowledge about socioeconomic variation in model inputs. The influence of 
socioeconomic variation differs between disease areas and settings. 
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Abstract 
Introduction 
A distribution of intervention impact across socioeconomic groups can be estimated from 
socioeconomic differences across a staircase from need (e.g. prevalence) up to intervention 
characteristics (e.g. effectiveness) using distributional cost effectiveness analysis (DCEA). The extent 
to which evidence on inequality at different steps of the staircase contributes to uncertainty in 
population level impact is not well understood. We used DCEAs in smoking cessation and alcohol 
interventions to explore how socioeconomic inequality in model inputs impacts upon final 
conclusions about health inequality and value for money. 
 
Methods 
Total population health and health inequality impacts were expressed using incremental net health 
benefit (NHB) and incremental ‘equally distributed equivalent’ (EDE) health, both measured in 
quality adjusted life years (QALYs). EDE reveals how the value of NHB is altered by inequality in its 
distribution. Scenario analyses explored: (i) the impact of ignoring socioeconomic differences in 
inputs; (ii) the value of eliminating differences; and (iii) how results differ between areas with 
different socioeconomic patterns. 
 
Results 
There was no discernible pattern relating the extent and direction of socioeconomic variation in 
model inputs to socioeconomic variation in model outputs. Differences in deprivation structure of 
the local population and other factors translate into different conclusions on the value for money of 
delivering the interventions locally compared to nationally. 
 
Discussion 
Our results suggest there is limited scope for informally assessing the importance of lack of 
knowledge about socioeconomic variation in model inputs. The influence of socioeconomic variation 
differs between disease areas and setting. 
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Executive Summary 
Background/Introduction 
Public health interventions can impact on total population health, and in doing so can alter the 
distribution of health within the population, which impacts on health inequalities. Inequality in 
health outcomes can be measured as an absolute difference between groups or individuals, as a 
relative difference, or in terms of the shortfall from some minimum standard. When health care 
decision makers are interested in improving health and reducing unfair health inequalities (i.e. 
reducing the perceived unfairness of the distribution of health across the population), they require 
tools that quantify changes in the distribution of health that result from the delivery of 
interventions. Where overall health improves but inequalities worsen, or vice versa, those tools 
should make explicit the trade-offs between them. Economic evaluations are routinely used to 
assess the impact of interventions on net health on average. This can be extended to characterise 
how net health benefits vary between groups in the population. For example, they may be used to 
determine the distribution of health outcomes across socioeconomic groups.  When combined with 
information on the baseline distribution of health across these groups, impacts on absolute, relative 
and shortfall health inequality can be quantified. These extensions, known as distributional cost 
effectiveness analyses (DCEA), provide valuable information on the extent of any trade-offs between 
improvements in overall health versus reduction in measures of health inequality. 
 
Uncertainty in the inputs to economic evaluation, including in the extent that variables differ 
between groups, translates into uncertainty over the results. For some inputs there may be a 
complete absence of evidence on the extent of socioeconomic variation. This uncertainty implies the 
possibility of an incorrect conclusion about intervention impacts, including impacts on total health, 
health inequality, and the overall value for money of an intervention. Sensitivity analysis can 
quantify how the uncertainty in inputs, including uncertainty in the extent of differences between 
groups, impacts on the uncertainty in the conclusions about an intervention’s effect on overall 
health and health inequality. Using sensitivity analysis, we can explore how absence of evidence on 
socioeconomic differences in disease and intervention characteristics could impact on conclusions 
about value for money. The cost of uncertainty can be estimated in terms of the potential loss of 
health and/or greater avoidable health inequality from an incorrect decision. This can then be used 
to inform decisions about whether it would be worthwhile obtaining more information to reduce the 
uncertainty. 
 
The between group differences in inputs may vary between settings, for example the prevalence of 
smoking by socioeconomic status may differ between areas with different ethnic composition. 
Evaluating the impact on the population distribution of health from national implementation of an 
intervention may, therefore, not be informative for the change in the distribution of health that 
would be expected at a local level. Therefore, it is relevant to local decision makers to understand 
how local level variation will impact on overall health and changes in health inequality, compared to 
the national level estimates. 
 
Aims 
This project aims to explore how models that characterise socioeconomic variation in the value of 
model inputs can be analysed to inform four broad questions: 
 
(a) How influential is a lack of knowledge about socioeconomic differences on conclusions about the 
impact on overall health and health inequality? 
(b) How valuable would it be to eliminate socioeconomic differences related to the intervention 
being considered? 
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(c) How generalisable are conclusions about impact on overall health and health inequality to 
contexts in which between group differences in the targeted populations differ? 
(d) To what extent do the answers to these three questions differ between two models in different 
disease areas, and what conclusions can we draw about the generalisability of their results to other 
interventions or disease areas? 
 
Methods 
Two case study models, previously developed to assess i) smoking cessation interventions and ii) 
brief interventions for alcohol misuse, were adapted to incorporate local level socioeconomic 
patterned data and to perform a range of scenario analyses. For the smoking cessation model, 
probabilistic sensitivity and value of information analysis was also performed. Both models consider 
costs (pound sterling, 2018 price year) under an NHS and personal social services perspective and 
measure health outcomes in quality adjusted life years (QALYs). 
 
Socioeconomic status is characterised by the Index of Multiple Deprivation (IMD). Outcomes 
considered are change in overall health, measured using incremental population net health benefit 
(i.e. health benefit of the intervention less health lost elsewhere as a result of resources not being 
available for other purposes) by assuming that £20,000 invested in other purposes produces one 
QALY. Change in health inequality is defined as the difference between the change in incremental 
health-related social welfare, measured using incremental equally distributed equivalent (EDE) 
health based on the Atkinson index, and change in incremental net health benefit. The Atkinson 
index describes the extent of welfare lost due to inequality in the population distribution of healthy 
life expectancy, based on UK population aversion to health inequality between rich and poor groups. 
The EDE is the amount of QALYs that, if equally distributed within the population, generate the same 
social welfare as the total QALYs in the distribution of health being evaluated. 
 
For both case study models, we: 
 
1. Describe socioeconomic ‘gradients’ in the model inputs, i.e. how the input values vary 
across the different socioeconomic groups. We distinguish between those gradients that are 
modifiable, and those that are exogenous (non-modifiable) and relate to the setting in 
which the intervention will be employed. The extent of socioeconomic differences in model 
inputs are summarised using concentration indices. 
2. Perform scenario analyses in which we explore: 
a. The impact of ignoring the socioeconomic differences in inputs on the model 
results, i.e. setting each input in all groups to the average; 
b. The potential value of eliminating the differences by ‘levelling up’ the model inputs 
for modifiable socioeconomic differences, i.e. setting the input to the ‘best’ value 
across groups; 
c. How the results differ when using data from local settings (Local Authorities) with 
different characteristics. 
 
The impact of each scenario is captured for pairwise comparisons by the change in incremental net 
benefit (iNHB), change in health-related social welfare (incremental EDE [iEDE] health) and change in 
inequality (iEDE-iNHB), compared to the base-case estimates. The pattern of socioeconomic 
differences in model inputs and the results of the scenario analyses are compared across the two 
case studies, to explore whether there are any patterns between the extent of inequality of model 
inputs and the estimated impact of the intervention on health inequality and other model outputs. 
 
The smoking cessation model is a cohort Markov model that assesses the cost effectiveness of two 
active interventions (Varenicline and 7.2mg e-cigarette) to quit smoking and ‘no intervention’ in a 
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cohort of adult smokers (18-75 years) over a lifetime horizon. The model includes three discrete and 
mutually exclusive health states: i) smokers, ii) former smokers and iii) death. Smokers and former 
smokers are at risk of 6 smoking related comorbidities, which are modelled as events with impact on 
costs and QALYs. Health-related quality of life (HRQoL) in each state is age and smoking status 
dependent. 
 
The Sheffield Alcohol Policy Model (SAPM) is a hybrid simulation/cohort modelling approach, 
incorporating two linked models that evaluates the cost effectiveness of screening and brief 
interventions (SBIs) to reduce alcohol misuse. Modelled strategies include delivery of SBIs to all 
patients when registering with a new primary care practice, or delivery to all patients as part of their 
next GP consultation. The first part of the model takes a baseline population of individual drinkers 
and simulates receipt of SBIs and the resulting age-adjusted trends in alcohol consumption over the 
20-year modelled time horizon. The second part of the model aggregates these individuals into 
cohorts based on gender, age, IMD quintiles and baseline drinking level. The model simulates 
changes in the risk of 45 alcohol related health conditions, which are then linked to changes in 
associated rates of mortality and hospital admissions. The results of this second part of the model 
are equivalent to a 47-state Markov trace (45 health conditions, no disease and dead) for each 
model subgroup over a 20-year time horizon. 
 
Both models consider socioeconomic gradients in baseline level of inequality (expressed in terms of 
the distribution of quality-adjusted life expectancy [QALE]), opportunity costs distribution, 
prevalence, mortality, comorbidities and intervention impact. However, there are differences in how 
the two models incorporate socioeconomic differences in prevalence and uptake. 
 
The smoking cessation model was also modified to incorporate parameter uncertainty, to be able to 
perform probability sensitivity analysis. The contribution of uncertainty in groups of associated 
model inputs for determining uncertainty in model outputs was assessed using two methods: value 
of information (VOI) analysis and analysis of covariance (ANCOVA). VOI estimates the value of 
resolving all of the uncertainty in a decision problem (related to all parameters) which determines 
the expected value of perfect information (EVPI). Similarly, VOI can be used to estimate the value of 
resolving the uncertainty in a subset of parameters (expected value of partial perfect information 
[EVPPI]). The value is expressed in terms of the health outcomes that could be gained by avoiding 
the potential for incorrect decisions. The ANCOVA method fits a general linear regression model to 
estimate the relative contribution of variation in parameter sets to variation in the results. The 
ANCOVA does not provide information on how uncertainty in model parameters impacts decision 
uncertainty and the consequences of making the wrong decision. Nevertheless, it is expected that 
parameters that contribute most to decision uncertainty would also be the ones that explain most 
variation in model outputs. For VOI, the EVPPI for each subset of parameters is reported as a 
proportion of the overall EVPI, with a higher value indicating more importance for determining 
uncertainty in outputs. For ANCOVA, the proportion of sum of squares explained by uncertainty in 
input parameters is reported. Uncertainty in model outputs is considered with respect to positive 
overall health (iNHB), positive health-related social welfare (iEDE) and positive reduction in 
inequality (iEDE-iNHB). 
 
Key findings and conclusions 
The two models share some common gradients in the socioeconomic distribution of baseline health 
and health opportunity costs, but differ in others. Smoking is more prevalent (i.e. is concentrated) in 
disadvantaged groups, while intervention effects and uptake are greater (are concentrated) in 
advantaged groups. In contrast, alcohol misuse is more prevalent in advantaged groups but 
intervention use is greater in disadvantaged groups. The base-case analysis suggested that, 
compared to ‘no intervention’, smoking cessation interventions would increase population health 
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but also increase health inequality. For the alcohol model, both interventions appear to increase 
population health and reduce health inequality, although screening all individuals at their next GP 
consultation does both, to a much greater extent than screening at next registration. 
 
(a) How influential is a lack of knowledge? 
Ignoring all of the gradients has considerable impact on the estimates of how interventions affect 
health inequality compared to base-case. The impact of a lack of knowledge about socioeconomic 
gradients on estimates of how interventions influence overall health appears minor in the smoking 
cessation model (0.21% decrease), while the results suggest a small underestimate (5.83%) for the 
alcohol model. A complete absence of information about the model inputs which are expected to 
differ by socioeconomic status seem to produce reasonably reliable estimates on overall health, but 
may lead to biased estimates on health inequality impact. 
 
Although a lack of knowledge of the gradient of individual parameters appears to affect overall 
health and health inequality in both models, there is no consistent pattern suggesting that any 
particular input is more influential across the two case studies. For the smoking cessation model, 
there is some suggestion of a positive correlation between the concentration index of inputs and the 
direction of impact on estimates of how interventions affect health inequality. In other words, 
ignoring the gradient in parameters that are more concentrated on the less deprived appears to 
diminish the extent by which the intervention alters the level of health inequality compared to base-
case. Ignoring the gradient in parameters concentrated on the most deprived results increases the 
extent to which the intervention is estimated to impact on health inequality. However, this pattern is 
not observed for the alcohol model. 
 
The probabilistic sensitivity analysis of the smoking cessation model revealed no decision 
uncertainty for the pairwise comparisons between each intervention and ‘no intervention’, for both 
impacts on overall health and health inequality. For these comparisons, uncertainty in overall health 
impact is mostly explained by uncertainty in the quit rate of the intervention and in intervention 
effectiveness, while uncertainty in uptake also explains uncertainty in the estimated health 
inequality impact. When comparing the two active interventions, there is decision uncertainty as to 
whether Varenicline increases overall health and reduces health inequality compared to e-cigarette. 
Value of information analysis suggests that the gradients that contribute the most to decision 
uncertainty, in terms of improvement in overall health, improvement in social welfare and reduction 
in health inequality, are the quit rates of the active interventions. 
 
(b) How valuable are modifications to reduce socioeconomic differences? 
Levelling up the model inputs related to the interventions across the whole population, to the 
highest level currently achieved in any socioeconomic subgroup, appears to result in greater gains in 
overall health and a reduction in health inequality (for the active interventions compared to ‘no 
intervention’) in both models. Given the potential to modify these inputs, decision makers may want 
to consider how delivery strategies for these health interventions can be improved so as to optimise 
the impact on both overall health and health inequality. 
 
(c) How generalisable are conclusions about value for money between settings? 
Results for specific local level settings are broadly consistent with those for England in terms of 
direction of change across scenarios and the influence of gradients in the results. This 
notwithstanding, local level differences in the socioeconomic gradients and population structure 
result in different conclusions on the value for money of interventions. Our findings suggest that 
Local Authority level decision making could be better supported by analysis incorporating data that 
reflects setting specific differences, as results cannot be inferred directly from national level data. 
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(d) How generalisable are these results between models and disease areas? 
Both models were amenable to incorporate socioeconomic differences in parameters modifiable 
and relating to the intervention, as well as those that are exogenous and relate to the setting, 
despite the different model structures. There was no discernible consistent pattern to relate the 
extent and direction of socioeconomic variation in model inputs to the socioeconomic variation in 
model outputs. This suggests that there is limited scope for informally assessing the importance of 
lack of knowledge about socioeconomic variation in model inputs outside of a distributional cost 
effectiveness analysis. 
 
The impact of reducing socioeconomic differences in the delivery and effects of interventions is 
positive for both improving overall health and reducing health inequality. Judgements on whether 
efforts to achieve this constitute value for money requires further study to estimate the additional 
costs associated with these efforts. 
 
Adoption of national recommendations at Local Authority level should be done cautiously. 
Differences in deprivation structure of the local population and other disease- and intervention-
related parameters, such as prevalence and uptake rate, may translate in different conclusions on 
the value for money of delivering the interventions locally compared to nationally. 
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Glossary  
Atkinson index An index that describes the extent by which the social welfare 
derived from a good is reduced by relative inequality in its 
distribution 
Concentration index An index that describes the level and direction of inequality in the 
distribution of a variable when the population is ranked by a second 
variable, ranging from -1 to 1 with negative/positive value indicating 




An economic evaluation that estimates who gains and who loses 
from an intervention and describes impacts on total health and 
health inequality 




The level of an outcome that, if given to all individuals in a 
population, generates the same amount of social welfare as the 
current distribution of that outcome 
Health inequality Differences in health outcomes between individuals or groups 
Index of Multiple 
Deprivation (IMD) 
An index that ranks every small area of England by a measure of 
deprivation derived from measures of income, employment, health, 
education, housing, crime and living environment 
Inequality aversion 
parameter 
A measure that describes the extent of preference for an equal 
distribution in terms of the amount of social welfare that could be 
gained by redistributing an outcome such that everyone in a 
population receives an equal amount 
Net health benefit (NHB) A summary statistic that describes the value of an intervention in 
terms of health, where resources have been converted to health 
losses based on their opportunity cost 
Opportunity costs The value of resources expressed in terms of the outcomes forgone 
from alternative uses of those same resources 
Quality adjusted life 
expectancy (QALE) 
A measure of life expectancy that is weighted by the level of health-
related quality of life in which it is lived 
Quality adjusted life years  
(QALY) 
A generic measure of health that includes both the quality and the 
quantity of life lived. One QALY equates to one year in perfect health 
Socioeconomic 
characteristics 
Factors that describe social and economic status, such as 
occupation, education, income, wealth, and place of residence 
Socioeconomic distribution How an outcome is distributed among members of a population 
according to their socioeconomic characteristics 
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1. Introduction/Background 
When determining which public health interventions to implement, decision makers often consider 
the dual objectives of improving total population health and reducing unfair health inequality (1, 2). 
Information about how interventions impact on health inequality, as well as how they affect overall 
health, can therefore help to inform healthcare resource allocation decisions. Economic evaluations 
are routinely employed to assess the average impact of interventions on health outcomes and costs 
(3). Assessing value for money from these models entails comparing the health gain from an 
intervention to the health gain that would have been achieved with alternative investments. 
However, interventions that increase total population health may either increase or reduce health 
inequality at the same time. The intervention that provides the greatest increase in health may not 
be the intervention that provides the greatest reduction in health inequality. If decision makers 
determine value for money as a function of an intervention’s impact on both overall health and 
health inequality, the distribution of the intervention’s impact across the population is required to 
inform the decision. Where interventions increase health but increase health inequality, by 
favouring the most advantaged, the choice of intervention requires a value judgement about the 
trade-off between increases in overall health compared to reductions in health inequality. Similarly, 
where interventions reduce health inequality, by favouring the least advantaged, but do not increase 
overall health by more than alternative investments, the value judgement must be applied to the 
trade-off between improvements in health inequality compared to forgone population health. 
 
Economic evaluations can be extended to look at how health benefits vary between groups in the 
population, such as groups with different socioeconomic characteristics. This requires defining the 
population groups of interest, and then searching for and incorporating evidence on how the value 
of model inputs varies between groups. Once the model employed for the economic evaluation 
describes a distribution of outcomes, assessment of value for money can be informed by information 
on how the intervention changes inequality in this distribution, as well as how it may impact on the 
average or total net health benefit. These types of models, described as distributional cost 
effectiveness analyses (DCEAs) (4), can be useful in answering a number of questions that policy 
makers may have about how interventions impact on health inequality, and the extent of any 
potential trade-offs between improvements in overall health versus reduction in health inequality. 
Additionally, a question frequently asked when evaluating intervention impact on health inequality 
is whether anything can be done to modify the intervention in order to alter its distributional impact. 
For example, if uptake is socially patterned, policy makers may be interested in whether it is 
worthwhile investing in actions that modify uptake. Investigating how changes in model inputs 
contribute to changes in outputs can inform the scope, by determining how far modifying 
intervention characteristics could alter final outcomes. 
 
There are multiple sources of uncertainty in economic evaluation; when incorporating the 
differences between groups, the uncertainty in how the input values vary across groups will 
translate into uncertainty over the results. It is important to understand how lack of knowledge may 
impact on the uncertainty in the conclusions about an intervention’s impact on overall health and 
health inequality. This includes the possibility of an incorrect conclusion about impacts on health 
inequality, and on the value for money of an intervention. When considering trade-offs, for example 
between increasing overall health and reducing health inequality, decision makers may be interested 
to know whether they are trading an uncertain gain for a certain loss. In general, the cost of 
uncertainty is determined by the potential loss of health from an incorrect decision. This can inform 
decisions about whether it would be worthwhile obtaining more information (thereby reducing 
uncertainty in the model inputs) to reduce the uncertainty of the model results. Distributional cost 
effectiveness analysis can extend this value of information analysis to look at the cost of uncertainty 
in terms of the extent of avoidable health inequality. 
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In addition, the extent and nature of the between group differences in model inputs can vary 
between settings. This may translate into variation in the set of interventions that provide value for 
money between settings. This is an important consideration when local decision makers seek to 
interpret public health recommendations, in terms of how they may increase local population health 
and reduce health inequality in the local population. Policy makers may wish to know how far 
conclusions about impact on overall health and change in health inequality generalise to their 
setting. 
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2. Project aims/Objective 
This project aims to investigate how models that characterise socioeconomic variation in the value 
of model inputs can be analysed to inform a range of questions relating to the influence of 
socioeconomic variation in each input on conclusions about the impact on overall health and health 
inequality of different policies. 
 
Two case study models (one assessing smoking cessation interventions and the other assessing brief 
interventions for alcohol misuse) were employed in the analysis to consider four broad questions: 
 
(a) How influential is a lack of knowledge about socioeconomic differences on conclusions about the 
impact on overall health and health inequality?  
(b) How valuable would it be to eliminate socioeconomic differences related to the intervention? In 
other words, what is the potential impact on population overall health and health inequality of 
interventions that eliminate differences, and for which inputs would it be most valuable to eliminate 
differences? 
(c) How generalisable are conclusions about impact on overall health and health inequality to 
contexts in which the between group differences in the targeted population differ? 
(d) To what extent do the answers to these three questions differ between the case study models, 
and what conclusions can we draw about the generalisability of their results to other interventions 
or disease areas? 
 
2.1 How influential is a lack of knowledge? 
One aim was to determine how an absence of information about socioeconomic variation in the 
model inputs would impact on conclusions about value for money. This represents the current 
situation, in which interventions are prioritised based on economic evaluations that describe only 
the average impact on population health. We aimed to explore the impact of using only the average 
value for inputs which are expected to differ by socioeconomic status, i.e. to use the same value 
across all socioeconomic groups instead of describing the between group variation. 
 
Second, the model inputs incorporating socioeconomic variations differ in the extent of inequality 
and in the extent of their influence on the model results. Thus, it would be worth knowing how to 
determine the extent by which inequality in each of the model inputs affects the conclusion on 
overall health and health inequality. This can be explored by examining the changes in model 
outputs when ignoring the socioeconomic differences in one model input, i.e., comparing the results 
of setting the values of one model input in all groups to the average, with the results of 
incorporating the differences. This would help to identify which model input has the greatest 
influence on overall results, and allow us to determine whether there is any pattern or association 
between the most sensitive parameters and the most unequal parameters.  
 
We also aimed to show how probabilistic sensitivity analysis and value of information analysis can be 
employed to answer questions about the value of obtaining more information on socioeconomic 
variation. Related to this, we show how value of information analysis indicates the relative 
contribution of each model input to decision uncertainty, and dichotomous conclusions about 
whether the interventions increase overall health or reduce health inequality. We also show how 
analysis of covariance can be used to explore the link between variation in a model input and 
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2.2  How valuable are modifications to reduce socioeconomic differences? 
We aimed to show how scenario analysis can be used to quantify potential improvements in health 
and reductions in health inequality, which could be achieved by changing potentially modifiable 
factors in intervention delivery. We explored this by estimating the potential increase in overall 
health and the change in health inequality from ‘levelling up’ these factors across the whole 
population to the highest level currently achieved in any socioeconomic subgroup. These results can 
help to inform efforts to design and improve delivery strategies for health interventions, informing 
questions such as: what are the likely health and inequality impacts of universal versus targeted 
delivery of an intervention, or what is the value of further research on interventions that might 
improve the effectiveness in more disadvantaged groups? 
 
2.3 How generalisable are conclusions about value for money between settings? 
The impact of a health intervention on health inequality depends on contextual factors such as the 
distribution of the targeted disease or risk factor varied by socioeconomic status. Even if the extent 
by which a model input varies between groups is the same across settings, the socioeconomic 
composition of the local population may differ, which can lead to different conclusions about how 
interventions impact on health inequality. We aimed to explore how the results would differ when 
incorporating Local Authority level data to reflect differences not only in the socioeconomic 
distribution in the population but also potentially in model inputs varied by socioeconomic status 
between Local Authorities. We considered what information and presentation of results from a 
distributional cost effectiveness analysis might be useful in allowing local decision makers to infer 
how results may differ in their setting without conducting a new analysis. We aimed to show 
whether knowledge of socioeconomic differences at Local Authority affects the value for money 
conclusion in the local setting, compared to other Local Authorities with different characteristics, or 
for the nation as a whole. These results will help to improve the extent to which local public health 
policies are tailored to the local context. 
 
2.4 How generalisable are these results between models and disease areas? 
By performing these analyses using two different models for different interventions and in different 
disease areas, we aimed to assess the extent to which our conclusions about how the lack of 
information on differences in model inputs affects the results, how modifying gradients can improve 
outcomes and how results change between settings, might vary. This could provide insight into the 
extent to which our findings are generalisable beyond the specific disease areas and interventions 
that we have examined in this project, and how they might inform both model and policy 
development in other areas. 
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3. Design and Methods 
As a starting point, we take that value for money is determined as a function of change in the 
distribution of health, reflecting both the change in the level of overall health and change in 
inequality in its distribution. Socioeconomic status is characterised based on the Index of Multiple 
Deprivation (IMD), which is a weighted composite index measure of deprivation by geographical 
area combining level of deprivation information from the inhabitants for small areas in England (5). 
 
3.1 Metrics used for assessing outcomes 
3.1.1 Net health benefit 
In economic evaluation of health care interventions, a generic health outcome which captures both 
survival duration and health-related quality of life is typically used, such as the quality adjusted life 
year (QALY). In a public health system with a fixed budget, if an intervention is implemented which 
requires additional resources, there would be forgone health associated with not using that funding 
for other health-improving services. Therefore, the benefits of the intervention should be assessed 
relative to those displaced when resources are diverted from alternative activities, i.e. health 
opportunity costs. The National Institute for Health and Care Excellence (NICE) currently uses a cost-
effectiveness threshold of £20,000 to £30,000 per QALY, implying that for every £20,000 to £30,000 
additional funding required one QALY will be lost elsewhere in the NHS (6). 
 
The change in overall health is defined here in terms of the incremental population net health 
benefit (NHB). An intervention with a positive NHB is considered to improve overall health because 
the health gains generated from its use will outweigh the health forgone (health losses) resulting 
from resources not being available for alternative health care investments. Health outcomes are 
expressed as QALYs and costs in pounds sterling (2018 price year). An annual discount rate of 3.5% is 
applied to both costs and benefits in accordance with NICE guidance (13). The costs are converted to 
health opportunity costs using the lower band of the NICE threshold, i.e. £20,000 per QALY, and then 
subtracted from the QALYs gains to estimate the population net health benefit. 
 
The distribution in the direct health benefits from the intervention is informed by conditioning 
model inputs on socioeconomic status. The associated distribution of the healthcare costs must first 
be converted into a distribution of opportunity costs, before it can be used to calculate net health 
impacts. The opportunity costs may fall across different socioeconomic groups to those in which the 
healthcare resources are employed. As a change in the NHS budget is spent more on treating 
deprived groups, the distribution of the health opportunity cost falls more heavily on the more 
deprived. Therefore, these opportunity costs have a socioeconomic distribution. Taking money out 
of the budget to fund new interventions will disproportionately affect the care that disadvantaged 
groups are currently receiving. The additional costs of implementing a new intervention are 
converted to health opportunity costs, using the rate at which existing NHS activities produce health 
and then allocated to IMD quintile groups, following the distribution of health opportunity costs (7) 
(Table 1). For each group, the health opportunity costs are subtracted from the total QALYs benefits 
from the intervention in that group, to estimate the distribution of the incremental population NHB 
across socioeconomic groups in the population. 
 
Table 1. Distribution of health opportunity costs by IMD quintile groups 
Parameter  Value  Source  




IMD5 (least deprived) 0.14 
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3.1.2 Equally distributed equivalent health 
To assess the impact of the intervention on inequality in the level of health outcomes (as opposed to 
inequality in the change in health outcomes), the first step is to describe the baseline level of 
inequality. We express this in terms of the distribution of quality-adjusted life expectancy (QALE). 
QALE takes into account variation in both length and health-related quality of life (8). There is a 
social distribution of baseline QALE (before the intervention), as shown in Table 2. The distribution 
of incremental NHB due to intervention is then added to the distribution of baseline QALE to provide 
a picture of the distribution of QALE changes following the implementation of the intervention. 
 
Table 2. The social distribution of health in England 
 QALE at birth (years) Source 




IMD5 (least deprived) 75.6 
 
To integrate the dual objectives of increasing total health and reducing health inequality, we use a 
single index measure of health-related social welfare, which formally combines both impacts using a 
health-related social welfare function. The welfare or value of a distribution of health can be 
characterised by defining an aggregation function that includes an inequality aversion parameter, 
which describes the amount of overall health that a decision maker would be willing to sacrifice to 
achieve a more equal distribution. A higher value assigned to the inequality aversion parameter 
reflects a greater concern for inequality at the lower end of the distribution. The existing empirical 
work has produced the estimates of level of inequality aversion in the UK, which provides us with an 
inequality aversion parameter based on elicited valuations from the general population (9). 
 
We define the social welfare value of population health as ‘equally distributed equivalent’ (EDE) 
health (expressed in QALYs) based on the Atkinson index. The Atkinson index (10) is an index that 
describes the extent by which social welfare is reduced by relative inequality in the distribution of an 
outcome, and is the most popular welfare-based measure of inequality. It ranges from 0 to 1, where 
0 represents no welfare loss from inequality and 1 represents complete welfare loss from inequality. 
‘Equally distributed equivalent’ health is the level of population health that, if distributed completely 
equally, yields an equivalent amount of social welfare to the distribution being evaluated. The 
Atkinson inequality aversion parameter of 10.95, estimated from a survey in the general public in 
England (9), is used to calculate EDE health. The EDE health pre- and post-intervention is calculated 
based on the distribution of baseline QALE and the distribution of QALE with the intervention 
respectively, with the incremental EDE health indicating the change in social welfare. 
 
The value of any change in health inequality expressed in terms of QALYs is defined as the difference 
between the change in incremental EDE health and change in incremental net health benefit. An 
intervention that reduces health inequality would have an incremental EDE health higher than its 
incremental NHB, with the difference showing the gain of health-related social welfare in terms of 
QALYs. 
 
3.1.3 Uncertainty analysis 
The uncertainty in the results is evaluated using the probability of incremental NHB (iNHB) being 
greater than zero (i.e., percentage of simulations with positive incremental NHB), the probability of 
incremental EDE (iEDE) being greater than zero (i.e., percentage of simulations with positive 
incremental EDE), and the probability of reducing inequality (i.e., percentage of simulations with 
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positive values in the difference between iEDE and iNHB). Results are also presented visually as 
scatter plots on the health equity impact plane. 
 
We further explore the importance of uncertainty in each group of associated parameters for 
determining uncertainty in model outputs using two methods: value of information (VOI) analysis via 
the SAVI (Sheffield Accelerated Value of Information) platform (27) and probabilistic analysis of 
covariance (ANCOVA) (28). VOI can be conducted including expected value of perfect information 
(EVPI) and expected value of partial perfect information (EVPPI). VOI characterises decision 
uncertainty by evaluating the health outcomes according to which intervention would be selected 
on the basis of a decision rule about value for money. It estimates the monetary value of resolving 
all of the uncertainty in a decision problem related to all parameters (EVPI) or a subset of 
parameters (EVPPI) (29) in terms of the health outcomes that could be gained by avoiding the 
potential error when selecting an intervention. In this case study, the VOI approach characterises 
uncertainty of parameters with respect to positive overall health (iNHB), positive health-related 
social welfare (iEDE) and positive reduction in inequality (iEDE-iNHB). ANCOVA method shows the 
relative effect of the variation in parameter sets to the variation in the results, by fitting a general 
linear regression model (28). This is distinct from VOI because it does not incorporate a decision rule, 
and unlike the VOI analysis does not analyses variation across a decision threshold. In some 
circumstances, an outcome might be highly variable, but all plausible values may be on one side of 
the decision threshold, and so it may be associated with no decision uncertainty. In other 
circumstances, there may be little variation in the outcomes, but if it is concentrated around the 
decision threshold this might translate into higher levels of decision uncertainty. However, in general 
we would expect that the parameters that contribute most to decision uncertainty would also be the 
ones that explain most variation in the model outputs. For VOI, the index to overall EVPI for the 
subset of parameters is reported, with a higher value indicating more importance for determining 
uncertainty in outputs. For ANCOVA, the proportion of sum of squares explained by uncertainty in 
input parameters is reported. 
 
3.2 Approach for analysis 
We start by describing how the socioeconomic differences are characterised in both case studies in 
detail, and perform the scenario analyses separately to investigate the impact of the model inputs 
on conclusions about value for money. If the model successfully measures the average health impact 
and the gradients are implemented correctly, we would expect ignoring the gradients to have little 
impact on overall health but a large impact on health inequality. If ignoring the gradients impacts on 
overall health substantially, this suggests that the base-case is not a good characterisation of the 
average overall health, or that we have altered things in how we have characterised the gradient. 
We also compare the two models in terms of how the model inputs are characterised, inequality of 
model inputs, and their impacts on the results. For brevity we present selected results in the main 
report to illustrate each analysis, with the remaining results detailed in Appendix. 
 
First, the two case study models are described in terms of how they characterise differences 
between socioeconomic groups in the population. That is, the set of model inputs that take different 
values for different socioeconomic groups is described, along with the evidence to support these 
differences. The between group differences in each model input can be summarised broadly in 
terms of the ‘gradient’ (e.g. whether the input value is higher among the socioeconomically 
disadvantaged groups, whether it is higher among the socioeconomically advantaged groups, or 
whether there is no discernible pattern). The model inputs are characterised according to those that 
are modifiable and relate to the intervention, and those that are exogenous and relate to the setting 
in which the intervention will be employed. The level and direction of inequality in model inputs are 
summarised illustratively using the concentration index (11). This provides a summary measure of 
magnitude of socioeconomic-related inequality in a health variable of interest. It summarises the 
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distribution in one number, ranging from -1 to 1 with negative/positive value indicating greater 
concentration of health in more/less disadvantaged groups. 
 
Second, scenario analyses are used to explore: (i) the impact of ignoring the socioeconomic 
differences in inputs on the model results, e.g. setting mortality in all groups to the average; (ii) the 
potential value of eliminating the differences by ‘levelling up’ the model inputs with modifiable 
socioeconomic differences, e.g. uptake, to that of the ‘best’ group; and (iii) how the results differ 
when applying to local (i.e., Local Authority) populations with different characteristics. 
 
Each model describes how interventions change the level of overall health (population net health 
benefit) and inequality in its distribution. The health equity plane is used to jointly illustrate these 
changes. Interventions that improve overall health with a positive iNHB fall in the north of the plane 
(Figure 1 quadrant A and B). Interventions that reduce inequality with positive difference between 




  Health equity impact plane 
 
Third, model inputs incorporating socioeconomic differences and results of the scenario analyses of 
the two case studies are compared, to explore the possible pattern between the extent of inequality 
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4. Case study one: smoking cessation model 
An existing smoking cessation distributional cost effectiveness analysis (DCEA) was adapted to 
reflect uncertainty in the differences between socioeconomic groups. Uncertain model parameters 
were characterised as distributions with the uncertainty then propagated through the model using 
Monte Carlo simulation, i.e. probabilistic sensitivity analysis (PSA), to estimate uncertainty in model 
outputs, and determine the importance of uncertainty in each input for determining uncertainty in 
outputs. 
 
4.1 Overview of the model 
Details of the DCEA are reported elsewhere (12). In brief, the model evaluates the cost-effectiveness 
of smoking cessation strategies for adult smokers (18-75 years) from the NHS and personal social 
services perspective over the lifetime horizon. For simplicity, two active interventions from the 21 
strategies assessed in the original model: i) Varenicline (14), and ii) 7.2mg e-cigarette (15), and the 
‘no intervention’ strategy were included in this study. Varenicline is a prescription medication used 
to treat nicotine addiction which is expected to perform best in least deprived group; while e-
cigarette is a battery-operated device that smokers use to quit smoking, reduce cigarette 
consumption, and relieve tobacco withdrawal symptoms, which could potentially perform better in 
more deprived groups. Nevertheless, the model did not consider the differences in uptake rate 
between the two interventions, as this is beyond the scope of this study. 
 
The model is a cohort Markov model with the structure shown in Figure 2. The model includes three 
discrete and mutually exclusive health states: i) smokers, ii) former smokers and iii) death. The full 
cohort enters the model via the ‘smokers’ health state, and is exposed to the mortality and disease 
risks. Mortality differs by age and smoking status, with an age-specific relative risks (RRs) of death by 
smoking status applied to age specific all-cause mortality rates. The risk for developing smoking-
related disease also differs by age and smoking status. 
 
In each annual cycle, smokers have a probability of quitting smoking (and becoming ‘former 
smokers’). Those who receive ‘no intervention’ have a ‘background’ quit rate of 2% (proportion of 
current smokers who naturally quit each year), while those who receive the interventions have 
higher quit rates, based on the original studies reporting the efficiency of the interventions (14, 15). 
Smokers are assumed to receive the intervention in the first year, and intervention costs are applied 
in the first cycle. Since the second cycle, smokers have the background quit rate and the model 
allows for relapse of former smokers (i.e. moving from former smoker to smoker), but the relapse 
rate is set to zero to simplify the analysis. Smokers and former smokers are at risk of six smoking 
related comorbidities (modelled as events): lung cancer (LC), coronary heart disease (CHD), chronic 
obstructive pulmonary disease (COPD), myocardial infarction (MI), stroke, and asthma exacerbation 
(asthma). Health-related quality of life (HRQoL) in each state is age and smoking status dependent. 
Each comorbidity has an associated cost and disutility. As these are modelled as events, rather than 
states in the model, when one or more comorbidities occur, the full event cost and disutility are 
applied in that cycle. The mortality risks of each co-morbidity are reflected in the overall mortality 
rate applied to smokers and non-smokers. 
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  The NICE model structure for smoking cessation interventions 
 
4.2 Socioeconomic variations in model inputs  
The differences in model inputs across IMD quintiles characterised in the DCEA are described in the 
following sections. Uncertainty around each gradient, which was used for the PSA, is also 
summarised.  
 
4.2.1 Socioeconomic variation in the baseline health and behaviour 
Baseline health and behaviour correspond to the levels that would be observed with ‘no 
intervention’. Baseline quality-adjusted life expectancy, health opportunity costs, smoking 
prevalence, mortality, prevalence of smoking-related comorbidities, and health-related quality of life 
are all known to differ according to IMD. 
 
Gradients in baseline QALE and opportunity costs distribution  
As described in section 3.1, the social distribution of QALE was taken from Love-Koh et al (2015) (8) 
(Table 2) and the socioeconomic gradient in the opportunity costs of additional healthcare 
expenditure was taken from Love-Koh et al. (2016) (Table 1). It is clear that the QALE is higher in less 
deprived areas, and more healthcare expenditure is allocated to residents in the more deprived 
areas. No uncertainty was assigned to these two gradients. 
 
Gradient in smoking prevalence 
The gradient in smoking prevalence by IMD quintiles was estimated using Public Health England 
Local Tobacco Control Profiles 2017 data. The smoking prevalence for each IMD quintile and 95% 
confidence intervals were available (Table 3). Smoking prevalence is higher in more disadvantaged 
areas. For smoking prevalence, we assigned independent Beta distributions to describe prevalence 
in each IMD quintile in order to reflect uncertainty in the PSA. Parameters that characterised the 
Beta distributions were estimated using the mean value and 95% confidence interval for smoking 
prevalence (Table 3). 
 
Table 3. Smoking prevalence by IMD in England (2017) 
Smoking prevalence  Mean 95% confidence interval 
IMD1 (most deprived) 17.17% 16.55%, 17.79% 
IMD2 15.96% 15.22%, 16.70% 
IMD3 14.09% 13.24%, 14.95% 
IMD4 12.68% 11.80%, 13.57% 
IMD5 (least deprived) 11.38% 10.53%, 12.24% 
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Gradient in mortality 
The annual mortality rates for smokers were estimated using the general population all-cause 
mortality by age and sex according to IMD quintiles, proportion of smokers, former smokers and 
non-smokers, and relative risk of death (smokers vs non-smokers by age group and smokers vs 
former smokers) (see equation 1 for details). 
 
Equation 1: Annual mortality rate for smokers= All cause annual mortality rate(proportion of smokers + proportion of former smokersrelative risk of death (smokers vs former smokers) + proportion of non smokersrelative risk of death (smokers vs non smokers) 
 
Data on all-cause mortality were extracted from the Office for National Statistics (ONS) data 2010-
2015 (16). Data on proportion of smokers, former smokers and non-smokers were estimated in the 
previous version of the model (12) and used in this study. The relative risk of death for smokers vs 
non-smokers by age group (35-44, 45-54, 55-64, 65-74 and 75+ years) and associated 95% 
confidence intervals were estimated using mortality data reported in a previous UK observational 
study (17). The study also provided mortality rates for former smokers to enable estimates of 
relative risk of death for smokers vs non-smokers although this was not stratified by age. Therefore, 
it was assumed that the relative risk of death for smokers vs former smokers was constant across 
age groups. 
 
Uncertainty in the estimates of all-cause mortality and proportions were not available, therefore no 
uncertainty is reflected regarding the underlying mortality rate conditioned on IMD. However, the 
use of relative risks of death (which are sampled from lognormal probability distributions) allows us 
to reflect some of the uncertainty in these estimates. Socioeconomic variation in annual mortality 
risk for smokers is presented in Figure 3, showing a higher death rate in more deprived areas. 
 
 
  Socioeconomic variation in annual mortality risk for smokers 
 
Gradient in smoking-related comorbidities 
Incidence of smoking-related comorbidities was estimated in the previous version of the model (12), 
conditioned by age, sex and smoking status, but no information was available by socioeconomic 
status. A previous study in Scotland examined the relative risk of developing comorbidities by 
Scottish IMD (18), but similar information was not available for the English IMD. We assumed 
evidence on incidence of comorbidities was that in the middle IMD, i.e. IMD3 group, and then 
applied these relative risks to estimate the incidence by IMD. 
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Similar to the English IMD, the Scottish IMD provides a wealth of information on the small areas in 
Scotland and ranks all these areas from most deprived to least deprived (19). We assumed that the 
variation by SIMD was transferable to the English population. Relative risks and associated 
confidence intervals for each IMD (with IMD5 as the reference) were reported in that study and 
presented in Table 4, suggesting a higher probability of developing comorbidities for the less 
deprived areas. Since the study (18) did not run separate analysis for smokers and former smokers, 
we assumed the relative risk of developing comorbidities applied to both smokers and former 
smokers in each IMD quintile. The study did not report the variance-covariance matrix for the 
regression model, and so independent lognormal distributions were assigned to the log value of 
each of the relative risks. Thus, the independent distributions fail to control for the correlation 
between these parameters in the PSA. 
 
Table 4. Relative risk of developing smoking-related comorbidity 
Parameter  Value 95% confidence interval Distribution Source 
IMD1 (most deprived) 1.15 1.06, 1.24 Lognormal* Eberth et al. 
2014 
(18) 
IMD2 1.12 1.03, 1.20 Lognormal* 
IMD3 1.12 1.04, 1.21 Lognormal* 
IMD4 1.08 1.00, 1.17 Lognormal* 
IMD5 (least deprived) 1 - - 
*Estimates transformed to the log scale 
 
Gradient in health-related quality of life (HRQoL) 
The gradient in HRQoL was incorporated by estimating baseline HRQoL for smokers and former 
smokers without pre-existing circulatory and respiratory conditions by IMD quintiles. EQ-5D data in 
the Health Survey for England datasets (2012 and 2014) were used, comprising 4,960 observations 
with complete information on EQ-5D, age, IMD and smoking status. Ordinary least squares (OLS) 
regression was performed, with EQ-5D score as the dependent variable, and age group, smoking 
status (smoker/former smoker), and IMD quintile as explanatory variables. As previous work by 
Love-Koh et al (2018) (12) showed that the impact of smoking on HRQoL did not vary between IMD 
quintiles, we did not include interaction terms in the final model. The regression output used to 
predict the EQ-5D scores used in the economic model is reported in Table 5. The less deprived areas 
tend to have higher HRQoL. The variance-covariance matrix was extracted, and the corresponding 
Cholesky decomposition was used to obtain correlated draws from a multivariate normal 
distribution for use in the PSA. The regression coefficients were applied in the model to estimate EQ-
5D values disaggregated by smoking status, age and IMD quintiles. 
 
Table 5. Output from HRQoL regression model 
Variable 
 




Age group 16-24 Ref  
 25-34 -0.0124*** 0.0137 
 35-44 -0.0544*** 0.0133 
 45-54 -0.0681*** 0.0135 
 55-64 -0.0986*** 0.0138 
 65-74 -0.107*** 0.0145 
 75+ -0.1630*** 0.0165 
Smoking status Former smoker Ref  
 Smoker  -0.0340*** 0.0069 
IMD IMD1 (most deprived) Ref 
 
 IMD2 0.0320** 0.0099 
 IMD3 0.0281** 0.0101 
 IMD4 0.0545*** 0.0102 
 IMD5 (least deprived) 0.0736*** 0.0101 
Adjusted R-squared  0.0414  
*p<0.05, **p<0.01, ***p<0.001 
Comparing smoking cessation to screening and brief intervention for alcohol in distributional cost effectiveness analysis  19 
4.2.2 Socioeconomic variation in intervention impact 
Socioeconomic variations in intervention effectiveness, i.e. smoking quit rate, and the intervention 
uptake rate were incorporated  
 
Gradient in intervention effectiveness 
The 12-month quit rates of the interventions Varenicline and 7.2mg e-cigarette (e-cigarette) were 
extracted from the original studies (14, 15). The 12-month quit rate for ‘no intervention’ was 2% (20) 
and is the proportion of current smokers who spontaneously quit each year. As there was no 
information on socioeconomic status in the original studies reporting the quit rates of the 
interventions, it was assumed that the quit rates represent the IMD3 group. The relative risk of quit 
smoking by IMD was estimated using results of the Evaluating Long-term Outcomes of NHS Stop 
Smoking Services (ELONS) study (21). The ELONS study assessed all English stop smoking services 
and, therefore, the results are reflective of a mix of interventions. We assumed the same gradient in 
effectiveness in both interventions. We also assumed that the natural quit rate would follow the 
same socioeconomic pattern as the interventions. We then applied these to estimate the quit rate 
by IMD. 
 
The ELONS study (21) reported the odds ratios of smoking cessation at 4 weeks by IMD quintiles, in 
relation to IMD1. It was assumed that the pattern observed at 4 weeks was reflective of that at 12 
months as a result of a lack of similar data at 12 months. The method suggested by Grant (2014) (22) 
was used to convert the odds ratios and 95% confidence intervals, estimated in one multivariate 
regression model, to relative risks of quitting smoking (see Table 6 for details). As the variance-
covariance matrix was not available for the regression model, independent lognormal distributions 
were assigned to the log value of each of the relative risks to reflect uncertainty for the PSA. 
 
Uncertainty surrounding the quit rates of the two interventions were extracted from the original 
studies, and we assigned a Beta distribution to both to reflect uncertainty for the PSA. No 
uncertainty was assumed for the natural quit rate. 
 
Table 6. Relative risk of quitting smoking 
Parameter  Value 95% confidence interval Distribution Source  
IMD1 (most deprived) 1 -  Dobbie et al. 2015 (21) 
Grant 2014 (22) IMD2 1.35 0.94, 1.81 Lognormal* 
IMD3 1.22 0.79, 1.73 Lognormal* 
IMD4 1.27 0.91, 1.67 Lognormal* 
IMD5 (least deprived) 1.36 0.94, 1.82 Lognormal* 
*Estimates transformed to the log scale 
 
Gradient in intervention uptake 
The gradient in intervention uptake was estimated using the proportion of smokers supplied with an 
intervention from NHS Stop Smoking Services by IMD quintiles, estimated by Love-Koh et al. (2018) 
(12). The results are presented in Table 7, and suggest that a greater proportion of smokers in the 
less deprived groups (IMD4 and IMD5) are utilising the services compared to the more deprived 
quintiles. As there was no data on the uncertainty surrounding these estimates, we assumed a 
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Table 7. Annual service uptake rate 
Parameter  Value Source  




IMD5 (least deprived) 9.92% 
 
4.2.3 Additional gradients not considered 
Gradient in comorbidity costs 
We assumed that a given smoking-related comorbidity event would incur the same costs regardless 
of IMD. To reflect uncertainty in comorbidity costs, we assumed the standard error was equal to 
10% of mean value and assigned Gamma distributions. 
 
Gradient in comorbidity disutility 
The previous work by Love-Koh et al (2018) (12) did not identify any evidence to suggest variation in 
the overall health-related quality of life impact of smoking by socioeconomic status. Therefore, we 
applied the disutility due to each comorbidity event as absolute decrements to the baseline HRQoL 
estimates. Mean estimates and standard errors for the disutility were extracted from several studies 
(23-26) (see Table 8 for details), and a Gamma distribution was assigned to reflect the uncertainty in 
the PSA. 
 
Table 8. Disutility due to co-morbidity 
Comorbidity  Mean Standard error Source 
Stroke 0.4839 0.0461 (23) 
Lung cancer 0.4233 0.1003 (23) 
MI 0.1878 0.0334 (23) 
CHD 0.2409 0.0122 (24) 
COPD 0.2700 0.0416 (25) 
Asthma exacerbation 0.3567 0.0694 (26) 
CHD: coronary heart disease; COPD: chronic obstructive 
pulmonary disease; MI: myocardial infarction. 
 
4.2.4 Summary of model inputs 
The model inputs described above can be characterised into two broad categories: non-modifiable, 
which are related to the disease and the population groups of interest; and potentially modifiable, 
which are related to the interventions (Table 9). Concentration indices of model inputs are also 
summarised in Table 9 and presented in Figure 4. Among all the model inputs incorporating 
socioeconomic differences, baseline QALE, HRQoL, intervention effectiveness, and intervention 
uptake have positive concentration indices, showing higher values in less deprived groups, while the 
others have negative concentration indices, suggesting higher values in more deprived groups. The 
greatest dispersion is in intervention uptake, which favours the less deprived. 
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Table 9. Category and concentration index of model inputs incorporating socioeconomic variation 
Category: Gradient in: Concentration index 
Non-modifiable  Baseline QALE 0.03 
 Health opportunity costs -0.12 
 Smoking prevalence -0.08 
 Mortality -0.08 
 Smoking-related comorbidities -0.02 
 HRQoL 0.01 
Potentially modifiable  Intervention effectiveness 0.04 
 Intervention uptake 0.17 




  Concentration index of model inputs 
 
4.2.5 Socioeconomic variation at Local Authority level 
To explore the generalisability of results to different contexts, information reflecting socioeconomic 
variations between Local Authorities in England was obtained. Smoking prevalence could be defined 
at Local Authority level using data from the Public Health England Local Tobacco Control Profiles, 
with socioeconomic status reported according to the National Statistics Socio-Economic 
Classification (NS-SEC). Mapping between the NS-SEC and IMD quintiles was performed and then 
combined with the prevalence for each NS-SEC group, to estimate the smoking prevalence for IMD 
quintiles at local level. The distribution of NS-SEC groups by IMD quintiles is summarised in Appendix 
Table S1.  
 
In this case study, we explore the results for York and Sheffield. The two Local Authorities were 
chosen to reflect the different pattern of population distribution by IMD (extracted from Public 
Health England Local Authority Health Profile 2017 and shown in Figure 5). There are more residents 
in York living in the least deprived area and more residents in Sheffield living in the most deprived 
area. In the absence of more detailed data at Local Authority levels, both Local Authorities are 
assumed to differ from the national model only on the basis of the deprivation structure of their 
respective populations and the smoking prevalence, i.e. the mortality risks, risks of comorbidities 
and HRQoL are the same for IMD quintiles in the national and both local models. The smoking 
prevalence in York and Sheffield is illustrated in Figure 6. 
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  Population distribution according to IMD in York and Sheffield 
 
 
  Variation in socioeconomic gradients in smoking prevalence for England, York and Sheffield 
 
4.3 Analysis 
4.3.1 Base-case analysis 
The analysis is conducted for the two interventions and ‘no intervention’. The incremental NHB, 
incremental EDE, and difference between incremental EDE and incremental NHB are estimated for 
all the pairwise comparisons (interventions vs ‘no intervention’; Varenicline vs e-cigarette). The 
analysis is conducted based on adult smokers only and our baseline population size is 42,994,944 (all 
adults in England), distributed between IMD quintiles based on ONS mid-year population estimates 
for 2017 as shown in Table 10. For York and Sheffield, the total population size was extracted from 
Public Health England Local Authority Health Profile 2017 (York: 207,000 and Sheffield: 574,000). 
 
Table 10. Baseline distribution of the adult population of England 
 Adult population 
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4.3.2 Scenario analysis 
A series of scenario analyses are performed to explore the impacts of gradients on conclusions about 
overall health and health inequality:  
 
(a) The impact of ignoring all gradients is explored, by setting the model inputs in all groups to the 
average value. 
(b) For all the model inputs characterised with gradients, the impact of ignoring the differences in 
one model input on the results is explored, by setting the value of that model input to the average 
value. 
(c) For the gradients that are potentially modifiable, the value of eliminating the differences is 
explored, by ‘levelling up’ to that of the ‘best’ group. 
 
The impact is captured by the change in overall health (iNHB), change in health-related social 
welfare (iEDE), and change in inequality (iEDE-iNHB), compared to the base-case. Results are 
summarised and presented visually on the health equity impact plane. 
 
4.3.3 Probabilistic sensitivity analysis 
The uncertainty in model inputs has been described previously with parameters characterised as 
distributions (section 4.2). Uncertainty in these parameters is then propagated through the model 
using Monte Carlo simulation (1,000 simulations). For each simulation the iNHB, iEDE, and difference 
between iEDE and iNHB (iEDE-iNHB), are estimated for all the pairwise comparisons. The uncertainty 
in the results is evaluated using the probability of iNHB being greater than zero (i.e., percentage of 
simulations with positive incremental NHB), the probability of iEDE being greater than zero (i.e., 
percentage of simulations with positive incremental EDE), and the probability of reducing inequality 
(i.e., percentage of simulations with positive values in the difference between iEDE and iNHB). 
Results are also presented visually as scatter plots on the health equity impact plane. The 1,000 sets 
of input values and corresponding outcomes from the Monte Carlo simulations are recorded for 
input into SAVI to undertake the VOI, and to facilitate linear regression for ANCOVA. 
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5. Case study two: alcohol Brief Interventions model 
The Sheffield Alcohol Policy Model (SAPM), an existing alcohol Screening and Brief Intervention (SBI) 
model used to inform NICE public health guidelines (30), has been adapted to quantify health equity 
impacts in subgroups defined according to socioeconomic status. In this study, we extended the 
model further to incorporate inequalities in health opportunity costs, in order to explore the key 
drivers of net inequality impacts in this area. 
 
5.1 Overview of the model 
Details of the model have been reported in full elsewhere (30). In brief, the model evaluates the 
delivery costs, downstream healthcare cost savings, and health impacts of alternative SBI delivery 
strategies from an NHS perspective. Modelled strategies include delivery of SBIs to all patients when 
registering with a new primary care practice, or delivery to all patients as part of their next GP 
consultation. Health outcomes are expressed as QALYs and costs in pounds sterling (2018 price 
year). Due to evidence that the effect of SBIs decays over time, with alcohol consumption estimated 
to return to age-adjusted pre-intervention levels after 7 years (31), and that there are delays 
between changes in alcohol consumption and changes in risk of harm, a 20 year time horizon is used 
(32). All costs and benefits are discounted at a rate of 3.5% in line with NICE guidance (13). For ease 
of exposition the present analysis focuses only on the comparison of 3 alternative scenarios: i) No 
SBI delivery, ii) All patients receiving an SBI when they register with a new GP practice and (Next 
Reg), iii) All patients receiving an SBI when they next visit their GP (Next Con). 
 
The basic structure of SAPM is a hybrid simulation/cohort modelling approach incorporating two 
linked models. The first model takes a baseline population of individual drinkers and simulates 
receipt of SBIs under each scenario and the resulting age-adjusted trends in alcohol consumption 
over the 20 year modelled time horizon. SBI delivery costs for each scenario are calculated in this 
model, accounting for the number of patients screened and the number of interventions delivered, 
using published estimates of practitioner time required for each stage (33). The second model 
aggregates these individuals into cohorts based on gender, age (4 groups: 18-24, 25-34, 35-54, 55+), 
IMD quintiles and baseline drinking level (3 groups: drinking within current UK guidelines of 14 
units/week (moderate); exceeding current guidelines but drinking no more than 50 units/week for 
men and 35 units/week for women (increasing risk); and drinking above these levels (high risk). 
Within these cohorts, within each year following baseline, the Potential Impact Fraction approach of 
Gunning-Schepers is used to estimate changes in rates of mortality and hospital admissions for 45 
different alcohol-related health conditions based on changes in alcohol consumption. The approach 
used to model changes in the risk of each health condition varies depending on whether the 
condition is associated with long-term chronic drinking or short-term acute intoxication, and 
whether the condition is exclusively caused by alcohol, or if alcohol is just a risk factor. The results of 
this model are equivalent to a 47-state Markov trace (45 health conditions, no disease and dead) for 
each model subgroup. HRQoL is calculated by assigning subgroup and condition-specific health state 
utilities within each model year. From this, the total number of QALYs accrued within each 
population subgroup in each year is calculated. Healthcare costs are calculated similarly using 
published health state-specific costs (33). The net cost of each intervention scenario is calculated by 
combining the intervention costs and downstream healthcare costs over the 20-year time horizon, 
after discounting. The total QALY gains are calculated similarly, divided by the initial population size 
and combined with the baseline QALE estimates from Table 2, to give estimates of the revised QALE 
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5.2 Socioeconomic variation in model inputs 
As for the smoking cessation model, socioeconomic status is characterised throughout the model 
using IMD. Socioeconomic gradients in key model inputs are described below, followed by a brief 
discussion of several key areas where potential gradients are not directly accounted for in the 
model. 
 
5.2.1 Socioeconomic variation in baseline health and behaviour 
Baseline levels of health and behaviour correspond to the levels that would be observed with ‘no 
intervention’. Prevalence of drinking, average consumption levels among drinkers, and patterns of 
drinking are all known to vary between IMD quintiles. There are also important gradients in baseline 
levels of mortality and disease prevalence for conditions which are related to alcohol consumption. 
 
Gradient in baseline QALE and opportunity costs distribution  
As for the smoking model, the social distribution of QALE was taken from Love-Koh et al (2015) (8) 
(Table 2) and the socioeconomic gradient in the opportunity costs of additional healthcare 
expenditure was taken from Love-Koh et al. (2016) (Table 1). 
 
Gradient in baseline drinking 
Alcohol consumption data comes from self-reported alcohol consumption of adults (aged 18+) in 
England taken from the pooled Health Surveys for England 2015 and 2016 (N=12,157). Three 
dimensions of consumption are used in SAPM: 1) whether an individual drinks alcohol at all, 2) the 
average weekly consumption of individuals who drink, 3) the consumption on the day of the 
previous week that the survey respondent drank the most, used as a proxy measure for binge 
drinking. Whilst SAPM’s individual-level nature accounts for age, gender and deprivation-level 
variation in drinking behaviours, the aggregated IMD quintile-level figures are summarised in Table 
11. In contrast to gradients in baseline smoking prevalence, those in more deprived groups are less 
likely to drink, drink less on average if they do drink, and ‘binge’ drink at lower levels. 
 
Table 11. Socioeconomic gradients in drinking 
Deprivation quintile Abstention rate 
Mean consumption 
(units/drinker/week) 
Peak day consumption 
(units/drinker) 
IMD1 (most deprived) 28.2% 13.00 4.44 
IMD2 32.0% 12.01 3.96 
IMD3 14.1% 12.54 4.33 
IMD4 12.3% 13.63 5.11 
IMD5 (least deprived) 7.1% 14.95 5.71 
 
Gradient in mortality 
Unlike the smoking cessation model, SAPM models outcomes separately by health condition, 
including 45 separate health conditions which are causally linked to alcohol, as well as mortality 
from all other causes combined. For each of these conditions, gradients in mortality were extracted 
from mortality records held by the ONS for the period from 2012-2016. Separate gradients were 
included in the model for each age-sex group for each condition. The implied population-level 
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  Socioeconomic variation in annual mortality rates 
 
Gradient in alcohol-related comorbidities 
Data on disease prevalence was obtained at the condition-specific level from analysis of Hospital 
Episode Statistics data for England for the period from 2012/13 to 2016/17. As individual admissions 
can have multiple diagnostic codes, each admission is coded to a single health condition using the 
‘broad measure’ approach, which is recommended by Public Health England as the most appropriate 
measure of ‘the total burden that alcohol has on community and health services’ (34). In order to 
prevent double-counting within the model, admissions within a year for the same individual are 
linked and where there are multiple admissions coded to different alcohol-related conditions within 
the same year, only the admissions for one condition are retained (see Jones et al. for a full 
description of this process (35)). Morbidity rates are calculated at the individual level (i.e. after 
removing repeat admissions for each individual). Population-level prevalence gradients are 
summarised in Figure 8. 
 
 
  Socioeconomic variation in prevalence of alcohol-related disease 
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5.2.2 Socioeconomic variation in intervention impact 
The intervention consists of two distinct steps – an initial ‘Screening’ step to identify individuals who 
are drinking at risky levels, and a secondary ‘Brief Intervention’ step. The overall gradient in receipt 
of the intervention is, therefore, the product of two distinct gradients: 
 
1. A gradient in who is screened 
2. A gradient in the rate at which screened patients are identified as risky drinkers 
 
Gradient in screening rates 
The rates at which different subgroups in the population are screened for risky alcohol consumption, 
using a validated tool such as the Alcohol Use Disorders Identification Tool (AUDIT) (36) depends on 
the scenario to be modelled. For the ‘next registration’ scenario, it is the rate at which individuals in 
each subgroup register with new GP practices. For the ‘next consultation’ scenario, it is the 
proportion of the population who attend primary care for any reason over the course of a year. Data 
on the rate of new GP registrations by socioeconomic status is derived from The Health 
Improvement Network (THIN), a database of computerised primary care patient records covering 
approximately 6% of the UK population (37). For each age-gender-deprivation subgroup included in 
SAPM, rates of new registrations were calculated from 2015-16 THIN data. The aggregated IMD 
quintile rates are shown in Table 12. Data on GP consultation frequencies are taken from the Health 
Survey for England, which included questions on whether a patient had seen a primary care 
practitioner in the preceding 12 months (Table 12). 
 
Table 12. Socioeconomic gradients in screening rates  
Deprivation quintile Next registration scenario Next consultation scenario 
IMD1 (most deprived) 9.4% 76.4% 
IMD2 12.6% 74.1% 
IMD3 12.8% 74.7% 
IMD4 11.2% 72.4% 
IMD5 (least deprived) 11.1% 72.9% 
 
Gradient in screen positive rates 
Screening tools such as AUDIT typically include a series of questions asking about drinking levels, as 
well as questions about whether the individual has suffered negative consequences from their 
drinking. Whilst gradients in drinking levels are already captured in the model as described above, 
there may be additional gradients in the likelihood of screening positive, arising from additional 
gradients in experiencing negative consequences. We, therefore, fitted a logistic regression to 
estimate the likelihood of screening positive for an individual, conditional on their mean 
consumption, age, sex and IMD quintile using data from the Alcohol Toolkit Study (38). The 
coefficients from this regression are shown in Table 13. 
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Table 13. Output from screening outcome regression model 
Variable 
 




Age group 16-24 Ref  
 25-34 0.4944*** 0.0216 
 35-54 0.2655*** 0.0105 
 55+ 0.0750*** 0.0035 
Sex Male Ref  
 Female  0.7267*** 0.0215 
Mean consumption (units/week)  1.2463*** 0.0029 
IMD IMD5 (least deprived) Ref  
 IMD4 1.1851*** 0.0436 
 IMD3 1.2540*** 0.0556 
 IMD2 1.2730*** 0.0668 
 IMD1 (most deprived) 1.7310*** 0.1120 
*p<0.05, **p<0.01, ***p<0.001 
 
 
5.2.3 Additional gradients not considered 
Several important gradients which are incorporated into the smoking cessation model are not 
considered explicitly within this application of SAPM. 
 
Gradient in intervention effectiveness 
Unlike many other public health interventions, several studies have found no evidence of a 
socioeconomic gradient in the effectiveness of alcohol Brief Interventions (39, 40), although this is 
largely due to a lack of primary studies exploring this area. In the absence of clear evidence of such a 
gradient, we therefore assume an equal relative effect for all individuals receiving a brief 
intervention of an 8.2% reduction in mean alcohol consumption, in line with the findings of the 
latest Cochrane review. 
 
Gradient in health-related quality of life 
As described previously, health outcomes in SAPM are essentially modelled as a 47-state Markov 
model, with separate states for each of the 45 alcohol-related health conditions included in the 
model, death, and the remainder of the population. For each of these states, health state utilities 
are taken from previously published research using the Health Outcomes Data Repository (41). 
Separate utilities for each condition have been estimated for each age-sex subgroup in the model, 
giving a total of 47x8=376 different utility values. It was not possible to further stratify these values 
by socioeconomic status, although population-level gradients in HRQoL are incorporated into the 
model, to some extent, through differing prevalences of the various health conditions across 
socioeconomic groups. 
 
Gradient in healthcare costs 
Similarly to utility values, healthcare costs are taken from previously published estimates and are 
calculated separated for each health condition and by age (41). It was not possible to disaggregate 
these costs further, although an overall socioeconomic gradient in costs is incorporated in the model 
through variations in disease prevalence across socioeconomic groups. 
 
5.2.4 Summary of model inputs 
As for the smoking model, the model inputs described above can be characterised as either 
exogenous or endogenous to the intervention (Table 14). Concentration indices of model inputs are 
also summarised in Table 14 and presented in Figure 9. Baseline QALE, drinking prevalence and 
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mean and peak consumption among drinkers have positive concentration indices, showing higher 
values in the less deprived groups, while the others have negative concentration indices, suggesting 
higher values in the more deprived ones. The greatest dispersion is in health opportunity costs, 
which are greater among the more deprived. In the potentially modifiable inputs, the screening rate 
has a low level of concentration in both scenarios, while the likelihood of an individual screening 
positive is more concentrated in more deprived groups. 
 
Table 14. Category and concentration index of model inputs incorporating socioeconomic variation 
Category: Gradient in: Concentration index 
Non-modifiable Baseline QALE 0.03 
 
Health opportunity costs -0.12 
 
Drinking prevalence 0.06 
 
Mean consumption 0.03 
 
Peak day consumption 0.06 
 
Alcohol-attributable mortality -0.07 
 
Alcohol-attributable morbidity -0.05 
 Probability of screening positive -0.01 
Potentially modifiable Population 
screened 
Next Registration -0.01 
 
Next Consultation -0.10 
 
 
  Concentration index of model inputs 
 
5.2.5 Socioeconomic variation at Local Authority level 
We explore the generalisability of our results across contexts, by utilising specific Local Authority-
level adaptations of SAPM which have been developed as part of an NIHR-funded project (42). In 
order to maximise the potential variation in results, we have selected two Local Authorities, 
Liverpool and Trafford, which have very different population structures, as illustrated in Figure 10. 
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 Population structure for modelled Local Authorities 
 
These Local Authority-level models include detailed estimates of the local levels and patterns of 
alcohol consumption and how this is distributed across the population, as well as data on local 
prevalence of and mortality from alcohol-related disease. Unlike the smoking model, this variation in 
baseline harm rates are based on data taken directly from each of the Local Authorities and, 
therefore, the baseline mortality and prevalence rates are able to vary from the national rates within 
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 Variation in socioeconomic gradients in model inputs for England, Liverpool and Trafford 
 
5.3 Analysis 
5.3.1 Base-case analysis 
As with the smoking model, we only model intervention delivery among adults (aged 18+) and, 
therefore, the population size shown in Table 10 is used. The model estimates the costs of 
intervention delivery and the cumulative discounted incremental NHS cost savings, as well as QALYs 
over a 20-year period after one year of intervention delivery. The incremental NHB, incremental 
EDE, and difference between incremental EDE and incremental NHB are then calculated for all the 
pairwise comparisons. 
 
5.3.2 Scenario analysis 
Scenario analyses are performed to explore the impact of the various socioeconomic gradients 
described in Section 5.2 on model results. 
(a) The impact of ignoring all these gradients is explored by setting the model inputs in all groups to 
the average value within each age-sex group. 
(b) The impact of ignoring each of the following gradients within the model is examined in turn: 
 Abstention 
 Mean consumption 
 Peak day consumption 
 Whether individuals are screened 
 The likelihood of screening positive 
 Baseline disease prevalence rates 
 Baseline mortality rates 
 Health opportunity cost 
For each of these analyses, the levels of the input are set at the average within each age-sex group, 
except for the health opportunity cost, which is assumed to be equal across all IMD quintiles. 
(c) An additional analysis, in which we take the potentially modifiable gradient in who within the 
population is screened and ‘level this up’, firstly to the maximum delivery level within each age-sex 
group, and secondly to the population maximum delivery level. 
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6. Comparison of models 
Both models consider the gradients in baseline QALE, opportunity costs distribution, prevalence, 
mortality, comorbidities and intervention impact. Due to the different behaviours affected by the 
intervention (i.e. smoking and drinking), the set of comorbid health conditions included varies 
substantially between models. There are also major differences in the structure of the models. The 
smoking model uses a Markov structure to model adult smokers (18-75 years) through their life, 
with the model stratified by smoking status (smoker/non-smoker/former smoker) and IMD quintiles. 
In contrast, the alcohol model uses a hybrid individual-level simulation/cohort Markov model to 
model post-intervention levels of alcohol consumption and harm, with the model stratified 
throughout by age, sex, drinking level and IMD quintile. This additional complexity in the alcohol 
model means that there is substantially more scope for non-linearity between model inputs and 
outcomes, particularly since the relationships between alcohol consumption, which is modelled as a 
continuous variable, and harm outcomes are predominantly non-linear in nature. 
 
There are also important differences in the way the models incorporate socioeconomic differences 
which warrant further discussion. First, the gradient in prevalence is defined using proportion of 
smokers across IMD quintiles in the smoking model, while the alcohol model incorporates gradients 
in drinking rate, mean consumption, and peak day drinking. Second, the gradient in intervention 
impact is incorporated using the odds of successful quit attempt and intervention uptake rates in the 
smoking model, while in the alcohol model, access to the intervention consists of two steps. The 
model comprises an initial step where individuals attending primary care are selected to be 
screened, and a second step where those individuals are screened with only those identified as 
drinking at potentially risky levels receiving an intervention, so gradients in both steps are 
incorporated. The summary of concentration indices for the model inputs incorporating 
socioeconomic differences in both models is presented in Figure 12. Negative concentration indices 
demonstrate higher levels of the input in more deprived groups, while positive indices demonstrate 
higher levels in less deprived groups. This illustrates that the smoking prevalence is higher in more 
deprived groups, while all three dimensions of alcohol consumption are higher in less deprived 
groups. The concentration indices for the smoking cessation intervention impact (effectiveness and 
uptake) show higher levels in less deprived groups, while those for alcohol interventions show the 
opposite. In this comparison between two models, we focus on the concentration index of the 
model input, but note that the actual gradient can vary in shape, even when the concentration 
indices are similar in magnitude, as the gradients for the majority of inputs in both models are non-
linear. 
 
In terms of modelling the Local Authority level results, both models consider local information on 
prevalence and population distribution, while most of the remaining gradients are still based on 
those for England, and therefore the heterogeneity may not be well reflected. For example, 
socioeconomic pattern in utilisation of the interventions may vary between Local Authorities. The 
alcohol model also considers the degree of alcohol consumption and mortality from alcohol-related 
disease at Local Authorities level, which may provide more information on the difference in 
intervention impact at local level. 
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 Concentration index of model inputs in both models 
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7. Findings: smoking cessation model 
7.1 Base-case analysis 
The base-case results are presented in Table 15.  Compared to ‘no intervention’, both interventions 
improve NHB (Varenicline: 123,749 QALYs; e-cigarette: 80,782 QALYs) and EDE (Varenicline: 106,553 
QALYs; e-cigarette: 70,002 QALYs), but increase health inequality (negative difference between 
incremental EDE and incremental NHB). The impact on overall health and health inequality impact 
are plotted in Figure 13. Compared to ‘no intervention’, both interventions lie in the north-west 
quadrant of the plane, indicating that they increase population health but increase inequality. 
Compared to e-cigarette, Varenicline improves NHB and EDE, but increases inequality (Table 15) and 
results are plotted in Figure S1. 
 
Table 15. Estimates of incremental NHB and incremental EDE in base-case analysis 
 iNHB iEDE Inequality (iEDE-iNHB) 
Varenicline vs ‘no intervention’ 123,749 106,553 -17,196 
e-cigarette vs ‘no intervention’ 80,782 70,002 -10,780 
Varenicline vs e-cigarette 42,968 36,551 -6,417 
NHB net health benefit; EDE equally distributed equivalent health 
 
 
 Equity impact plane showing the overall health and health inequality 
 
7.2 Scenario analysis 
The results of scenario analyses for Varenicline compared to ‘no intervention’ are summarised in 
Table 16 and plotted in Figure 14 and Figure 15. Results for the other two comparisons are 
presented in Table S2-S3 and Figure S2-S3. 
 
Ignoring all gradients  
Ignoring all gradients has little impact on the overall health (-0.21%) but increases EDE health by 
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Ignoring one gradient 
Ignoring the gradients (separately or jointly) does not appear to have a great impact on overall 
health (Figure 14). Ignoring gradients in baseline QALE and opportunity costs has little effect on 
estimated impact on overall health (Table 16). Ignoring gradients in smoking prevalence and 
comorbidities slightly increases the estimated intervention impact on overall health by 7,506 QALYs 
(6.07%) and 2,563 QALYs (2.07%), while ignoring gradients in effectiveness, mortality, uptake and 
HRQoL results in modest reductions in estimated overall health impact by 5,280 QALYs (-4.27%), 
1,929 QALYs (-1.56%), 492 QALYs (-0.40%) and 239 QALYs (-0.19%) (Table 16). 
 
Ignoring one individual gradient appears to affect the estimated impact on health inequality (Figure 
14). Ignoring the gradient in opportunity costs increases the amount by which the interventions are 
estimated to increase inequality, as does ignoring gradients in smoking prevalence and risk of 
comorbidities. Ignoring gradients in baseline QALE, mortality risks, HRQoL, effectiveness and uptake 
reduces the amount by which the interventions are estimated to increase inequality, with removal of 
the gradient in uptake making Varenicline inequality reducing, compared to ‘no intervention’. 
 
The same pattern is observed for the comparisons between e-cigarette and ‘no intervention’ and 
between the two interventions (Figure S2). Ignoring the gradient in uptake suggests Varenicline 
reduces health inequality more than e-cigarette (Table S3 & Figure S2). 
 
Levelling up to the best 
Levelling up the effectiveness to that of the group with the maximum effect increases the estimated 
gain in overall health and EDE health (Table 16); it reduces the amount by which the intervention is 
estimated to increase health inequality (Figure 15). Similarly, levelling up the uptake rate increases 
the estimated gain in overall health and EDE health (Table 16); it alters the health inequality impact 
substantially to make Varenicline inequality reducing compared to ‘no intervention’ (Figure 15). 
 
Similar results were obtained for the comparisons between e-cigarette and ‘no intervention’ and 
between the two interventions (Figure S3). 
 
Table 16. Estimates of incremental NHB and incremental EDE in base-case and scenario analysis 
 iNHB Change in iNHB 
from base-case 




Change in the impact 
on inequality 
compared to base-case 
Varenicline vs ‘no intervention’    
Base-case 123,749 - 106,553 - -17,196 Increase inequality 
(a) Ignoring all gradients 123,489 -260 (-0.21%) 123,489 16,936 (+15.89%) 0 No effect 
(b) Ignoring gradient in:       
  Baseline QALE 123,749 0 (0%) 123,747 17,194 (+16.14%) -2 Smaller increase 
  Health opportunity costs 123,749 0 (0%) 105,432 -1,121 (-1.05%) -18,318 Larger increase 
  Smoking prevalence 131,255 7,506 (+6.07%) 105,444 -1,109 (-1.04%) -25,811 Larger increase 
  Mortality 121,820 -1,929 (-1.56%) 106,991 438 (+0.41%) -14,829 Smaller increase 
  Comorbidities 126,312 2,563 (+2.07%) 107,883 1,330 (+1.25%) -18,429 Larger increase 
  HRQoL 123,511 -239 (-0.19%) 106,637 84 (+0.08%) -16,874 Smaller increase 
  Effectiveness 118,470 -5,280 (-4.27%) 106,463 -89 (-0.08%) -12,006 Smaller increase 
  Uptake 123,258 -492 (-0.40%) 124,781 18,228 (+17.11%) 1,523 Inequality-reducing 
(c) Levelling up to the best in:      
  Effectiveness 134,837 11,088 (+8.96%) 121,333 14,780 (+13.87%) -13,504 Smaller increase 
  Uptake 168,033 44,284 (+35.79%) 170,110 63,557 (+59.65%) 2,076 Inequality-reducing 
NHB net health benefit; EDE equally distributed equivalent health 
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 Equity impact plane showing scenario analysis results where gradients are ignored 
 
 

























































Varenicline vs no intervention
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7.3 Probabilistic sensitivity analysis 
The scatter plots on the equity plan are shown in Figure 16. 
 
Varenicline vs ‘no intervention’ 7.2mg e-cigarette vs ‘no intervention’ Varenicline vs 7.2mg e-cigarette 
   
  Scatter plots on equity impact plane 
 
For both interventions compared to ‘no intervention’, the probability of positive iNHB and the 
probability of positive iEDE are both 100%, while the probability of iEDE greater than i NHB is 0%. 
This suggests that there is no uncertainty around the result that both interventions improve 
population health and increase inequality, relative to ‘no intervention’. When comparing the two 
active interventions (Varenicline vs e-cigarette), the probability of Varenicline having greater NHB 
than e-cigarette is 74.90%, and the probability of Varenicline having greater EDE compared to e-
cigarette is 74.20%, and the probability that Varenicline reduces health inequality compared to e-
cigarette is 19.80% (Table 17). 
 
Table 17. Probability of improving overall health and reducing health inequality 
 Probability of: 
  iNHB>0 iEDE>0 iEDE>iNHB 
Varenicline vs ‘no intervention’ 100.00% 100.00% 0.00% 
e-cigarette vs ‘no intervention’ 100.00% 100.00% 0.00% 
Varenicline vs e-cigarette 74.90% 74.20% 19.80% 
 
The results of the value of information analysis for the comparison between Varenicline and e-
cigarette are presented in Figure 17. The EVPI per person is estimated to be £142,617,861 for the 
decision about improvement in overall health, and £94,657,996 for the decision about reduction in 
health inequality (Table S4). Results show that, for the decision about improvement in overall health, 
improvement in social welfare and reduction in health inequality, the uncertainty is mostly 
determined by uncertainty in the quit rate of Varenicline, followed by uncertainty in the quit rate of 
e-cigarette. None of the other uncertain gradients appear to contribute to the decision uncertainty 
for the comparison between the two active interventions. The value of further research into each 
input is shown by the EVPPI estimates in Table S4. 
 
The results from the ANCOVA are similar to those from the VOI analysis, with quit rates contributing 
the most to the variation in the incremental difference in outcomes between the two interventions 
(Figure 17). For the pairwise comparisons between each intervention and ‘no intervention’, the 
variation in iNHB and iEDE is mainly explained by the variation in the quit rate of the intervention 
and its effectiveness; the variation in health inequality is also explained by these, and by variation in 
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Varenicline vs e-cigarette 
Improvement in overall health (incremental NHB>0) 
  
 
Improvement in social welfare (incremental EDE>0) 
   
 
Reduction in health inequality (incremental EDE>incremental NHB) 
  
 Value of information analysis results using SAVI and ANCOVA 
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7.4 Local Authority level results 
The base-case results for York and Sheffield are presented in Table 18, Figure 18 (intervention vs ‘no 
intervention’) and Figure S5 (Varenicline vs e-cigarette). Sheffield has a much larger population than 
York (547,000 versus 207,000), but the relative difference in the intervention impacts by local area 
exceeds the relative difference in population size.  Compared to ‘no intervention’, both interventions 
are estimated to increase overall health and EDE health. However, the estimated impact on health 
inequality differs by area, with smaller impacts in York, and e-cigarette estimated to reduce health 
inequality for York but not for Sheffield. 
 
Table 18. Estimates of incremental NHB and incremental EDE in base-case analysis 













Varenicline vs ‘no intervention’ 659 651 -9 2,092 1,625 -467 
e-cigarette vs ‘no intervention’ 431 433 3 1,365 1,062 -303 
Varenicline vs e-cigarette 229 217 -11 727 563 -164 
NHB net health benefit; EDE equally distributed equivalent health    
 
  
 Equity impact plane showing the overall health and health inequality for Local Authority analysis 
  
Varenicline vs 
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To present comparable results for England, York and Sheffield, we estimate the impacts on overall 
health and health inequality per 100,000 adults. The qualitative results for Varenicline are the same 
in all settings: in both York and Sheffield, Varenicline is estimated to increase overall health and 
increase inequality. The amount by which Varenicline is estimated to increase inequality is greatest 
in Sheffield, followed by England, and then York (Figure 19). The same pattern between local areas 
and England is observed for iNHB and iEDE health is observed for e-cigarette compared to ‘no 




 Equity impact plane showing the overall health and health inequality for Local Authority analysis 
 
The detailed results of the scenario analysis are presented in Table S5 (York) and Table S6 (Sheffield). 
Compared to the results in England, ignoring all gradients affects both overall health and health 
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Scenario analyses of ignoring the gradients (Varenicline vs ‘no intervention’) are plotted in Figure 20 
(York) and Figure 21 (Sheffield). The direction of change in the estimated results of ignoring one 
gradient on overall health and health inequality is the same as that observed for England, but due to 
the different base-case results, the removal of a gradient in uptake or effectiveness makes the 
intervention inequality reducing, compared to ‘no intervention’ for York (Figure 20) but not so for 
Sheffield (Figure 21). 
 
 
 Equity impact plane showing scenario analysis results for York where gradients are ignored 
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The direction of change in the results from levelling up modifiable gradients compared to base-case 
follows the same direction in York and Sheffield as for England. However, due to the different base-
case results, levelling up either effectiveness or uptake makes the intervention inequality reducing 
for York (Figure 22), but not for Sheffield (Figure 23). 
 
 
 Equity impact plane showing scenario analysis results for York where levelling up to the best 
 
 
 Equity impact plane showing scenario analysis results for Sheffield where levelling up to the best 
 
The same pattern of the change in the results of ignoring gradients and levelling up gradients is 
observed for York and Sheffield as for England in the comparisons between e-cigarette and ‘no 
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Probabilistic sensitivity analysis results are shown in Table 19. In contrast with those for England, 
there is some uncertainty around the results the intervention increases health inequality compared 
to ‘no intervention’ (Varenicline: 37.2% and e-cigarette: 55.4%) for York, but not so for Sheffield. 
Similarly, there is uncertainty around the comparison between the two active interventions at Local 
Authority level (Table 19). The scatter plots on the equity plan are shown in Figure 24 (York) and 
Figure 25 (Sheffield). 
 
Table 19. Probability of improving overall health and reducing health inequality at Local Authorities 
 York Sheffield 
 Probability of: Probability of: 
  iNHB>0 iEDE>0 iEDE>iNHB iNHB>0 iEDE>0 iEDE>iNHB 
Varenicline vs ‘no intervention’ 100.00% 100.00% 37.20% 100.00% 100.00% 0.00% 
e-cigarette vs ‘no intervention’ 100.00% 100.00% 55.40% 100.00% 100.00% 0.00% 
Varenicline vs e-cigarette 76.50% 74.80% 18.00% 75.20% 74.70% 22.60% 
NHB net health benefit; EDE equally distributed equivalent health    
 
Varenicline vs ‘no intervention’ e-cigarette vs ‘no intervention’ Varenicline vs e-cigarette 
   
 Scatter plots on equity impact plane for York 
 
Varenicline vs ‘no intervention’ e-cigarette vs ‘no intervention’ Varenicline vs e-cigarette 
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Results of the value of information analysis are presented in Figure 26 (York) and Figure 27 
(Sheffield). At Local Authority level, the results of the comparison between Varenicline and e-
cigarette are consistent with that observed for England, with the exception that the decision 
uncertainty about reduction in health inequality is mainly driven by smoking prevalence and 
effectiveness for York (Figure 26). For York, VOI analysis is also conducted for the uncertainty around 
the results of reducing inequality when comparing the intervention (Varenicline or e-cigarette) and 
‘no intervention’. It is mostly determined by uncertainty in smoking prevalence, effectiveness and 
uptake. Overall EVPI and EVPPI estimates for uncertainty in iNHB and iEDE are available in Table S7 
(York) and Table S8 (Sheffield). ANCOVA shows similar results to the VOI analysis. 
 
Varenicline vs e-cigarette 
Improvement in overall health (incremental NHB>0) 
  
 
Improvement in social welfare (incremental EDE>0) 
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Varenicline vs ‘no intervention’ 
Reduction in health inequality (incremental EDE>incremental NHB) 
  
 
e-cigarette vs ‘no intervention’ 
Reduction in health inequality (incremental EDE>incremental NHB) 
  
 Value of information analysis results using SAVI and ANCOVA for York 
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Varenicline vs e-cigarette 
Improvement in overall health (incremental NHB>0) 
  
 
Improvement in social welfare (incremental EDE>0) 
  
 
Reduction in health inequality (incremental EDE>incremental NHB) 
  
 
 Value of information analysis results using SAVI and ANCOVA for Sheffield  
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8. Findings: alcohol brief interventions model 
8.1 Base-case analysis 
The main base-case results are presented in Table 20. For England, both interventions improve NHB 
(Next Reg: 4,336 QALYs, Next Con: 43,016 QALYs) and EDE (Next Reg: 4,780 QALYs, Next Con: 50,594 
QALYs). The incremental NHB and EDE compared to ‘no intervention’ are plotted in Figure 28. Both 
interventions lie in the north-east quadrant of the plane, indicating that they increase population 
health and reduce inequality, although screening all individuals at their next GP consultation does 
both to a much greater extent. 
 
Table 20. Estimates of NHB and EDE in base-case analysis 
 iNHB iEDE Inequality (iEDE-iNHB) 
Next Registration vs. ‘no intervention’ 4,336 4,780 444 
Next Consultation vs. ‘no intervention’ 43,016 50,594 7,578 
Next Consultation vs. Next Registration 38,680 45,814 7,134 
 
 
 Equity impact plane showing base-case impacts on health and health inequality 
 
8.2 Scenario analysis 
Results of the scenario analyses for the Next Registration and Next Consultation scenarios compared 
to ‘no intervention’ are summarised in Table 21-22 and plotted in Figure 29-30. Results for the 
incremental comparison between the two scenarios are shown in Table S9 and Figure S13-S14. 
 
Ignoring all gradients  
For the Next Registration scenario, ignoring all gradients in the model leads to a modest 6% 
reduction in the estimated NHB, but a substantial fall of 25% in the estimated EDE arising from the 
policy (Table 21). As a result, in this scenario the intervention is estimated to increase inequality 
overall, in contrast to the base-case finding of reduced inequality. Results for the Next Consultation 
scenario are broadly similar, with the inequality impact of the policy falling by 13% and the 
intervention estimated to increase rather than reduce inequality. The impact on the estimated NHB, 
however, runs in the opposite direction, seeing a 6% increase when all gradients are removed from 
the model (Table 21). 
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Ignoring one gradient 
Under a Next Registration approach, ignoring gradients in mean consumption, peak consumption, 
screening coverage, likelihood of screening positive, and the health opportunity cost increases the 
estimated reduction in inequality arising from the intervention, while ignoring gradients in 
abstention, disease prevalence and mortality rates, reduces the impact on inequalities, with removal 
of the gradient in morbidity estimated to make the programme inequality-increasing overall 
compared to ‘no intervention’ (Figure 29). Removal of most gradients increases the estimated NHB, 
by up to 17.4% in the case of the gradient in mean consumption, although ignoring gradients in 
abstention gradients reduces the NHB by 9.0%. 
 
For the Next Consultation scenario, the picture is broadly similar, with the exception that excluding 
the gradient on abstention increases the estimated reduction in inequality, rather than reducing it 
(Figure 29). Also, ignoring all gradients except (by definition) opportunity costs, increases the 
estimated NHB by up to 10.4% in the case of the gradient in peak consumption. Unlike the scenario 
where all gradients are ignored, the removal of any single gradient is not sufficient to change the 
overall conclusion that the intervention is health-improving and inequality-reducing. 
 
Table 21. Estimates of NHB and EDE for scenario analyses 
  
  
iNHB Change in iNHB 
from base-case 




Change in the impact 
on inequality 
compared to base-case 
Next Registration vs. ‘no intervention’ 
    
Base-case 4,336 - 4,780 - 444 Reduces inequality 
(a) Ignoring all gradients 4,083 -253 (-5.83%) 3,580 -1199 (-25.08%) -503 Increases inequality 
(b) Ignoring gradient in: 
      
Baseline QALE 4,336 0 (0%) 4,336 -444 (-9.29%) 0 No effect 
Health opportunity costs 4,336 0 (0%) 4,989 209 (+4.37%) 652 Larger reduction 
Drinking prevalence 3,947 -389 (-8.97%) 4,125 -655 (-13.7%) 178 Smaller reduction 
Mean consumption 5,092 756 (+17.44%) 6,253 1474 (+30.84%) 1,162 Larger reduction 
Peak consumption 4,724 388 (+8.95%) 5,421 642 (+13.43%) 698 Larger reduction 
Morbidity 4,856 519 (+11.97%) 4,645 -135 (-2.82%) -211 Increases inequality 
Mortality 4,530 194 (+4.47%) 4,565 -215 (-4.5%) 35 Smaller reduction 
Screening coverage 4,493 157 (+3.62%) 5,492 713 (+14.92%) 999 Larger reduction 
Screening positive 4,803 466 (+10.75%) 5,512 732 (+15.31%) 709 Larger reduction 
Next Consultation vs. ‘no intervention’ 
    
Base-case 43,016 - 50,594 - 7,578 Reduces inequality 
(a) Ignoring all gradients 45,730 2715 (+6.31%) 44,045 -6548 (-12.94%) -1,685 Increases inequality 
(b) Ignoring gradient in: 
      
Baseline QALE 43,016 0 (0%) 43,016 -7578 (-14.98%) 0 No effect 
Health opportunity costs 43,016 0 (0%) 51,185 591 (+1.17%) 8,169 Larger reduction 
Drinking prevalence 45,518 2502 (+5.82%) 56,586 5993 (+11.85%) 11,068 Larger reduction 
Mean consumption 44,710 1694 (+3.94%) 54,590 3996 (+7.9%) 9,880 Larger reduction 
Peak consumption 47,494 4478 (+10.41%) 58,383 7789 (+15.4%) 10,888 Larger reduction 
Morbidity 45,172 2157 (+5.01%) 46,760 -3834 (-7.58%) 1,588 Smaller reduction 
Mortality 44,169 1153 (+2.68%) 47,828 -2766 (-5.47%) 3,659 Smaller reduction 
Screening coverage 45,824 2809 (+6.53%) 55,070 4476 (+8.85%) 9,245 Larger reduction 
 Screening positive 45,061 2045 (+4.75%) 55,537 4944 (+9.77%) 10,476 Larger reduction 
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 Equity impact planes showing results in the scenario analysis where gradients are ignored 
 
Levelling up to the best 
Table 22 presents the estimated impacts of increasing coverage of each intervention to both the 
age-sex specific and population maximum level. These results are illustrated in Figure 30. The 
incremental comparison of Next Consultation vs. Next Registration scenarios is shown in Table S9 
and Figure S14. For both interventions, increasing coverage increased NHB and further reduced 
inequalities than the base-case. For the Next Registration scenario, the marginal increases in both 
NHB and EDE was substantially greater between the age-sex and global maxima, compared to 
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Table 22. Estimates of the NHB and EDE in the base-case and ‘levelled-up’ analysis 
 
iNHB 
Change in iNHB 
from base-case 
iEDE 




Change in the impact 
on inequality 
compared to base-case 
Next Registration vs ‘no intervention’     
Base-case 4,336 - 4,780 - 444 Reduces inequality 
Levelling up to the best in:     
Screening rates (age-sex optimum) 4,817 480 (+11.07%) 6,213 1433 (+29.98%) 1,397 Larger reduction 
Screening rates (global optimum) 17,893 13556 (+312.64%) 22,141 17361 (+363.2%) 4,248 Larger reduction 
Next Consultation vs ‘no intervention’      
Base-case 43,016  50,594  7,578 Reduces inequality 
Levelling up to the best in:       
Screening rates (age-sex optimum) 55,436 12420 (+28.87%) 67,802 17208 (+34.01%) 12,366 Larger reduction 
Screening rates (global optimum) 61,716 18700 (+43.47%) 75,673 25079 (+49.57%) 13,956 Larger reduction 
 
  
 Equity impact plane for increased intervention coverage scenarios 
 
8.3 Local Authority level results 
The differences in modelled impacts of both policies in Liverpool and Trafford are shown in Table 23. 
In spite of the radically different population structures, the results are very similar, although 
differences in the baseline population sizes (England = 43m, Liverpool = 376k, Trafford = 174k) mean 
that the absolute magnitudes of effect are quite different. We, therefore, also present effects per 
100,000 population. In both areas, the Next Registration scenario is estimated to increase NHB and 
reduce inequality, while the Next Consultation scenario does both to a much greater extent after 
adjusting for the differences in population. This is illustrated in Figure 31. For both modelled policies, 
the estimated impact per 100,000 people on overall health is greater in Liverpool and Trafford sees a 
larger effect on health inequality, likely driven by the very different deprivation structures of the 
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Table 23. Estimated impacts of SBI programmes in Liverpool and Trafford 
 
iNHB iEDE Inequality (iEDE-iNHB) 
Next Registration vs. ‘no intervention’    
England Total 4,336 4,780 444  
Per 100,000 10 11 1 
Liverpool Total 79 88 9  
Per 100,000 21 23 2 
Trafford Total 31 37 6  
Per 100,000 18 21 3 
Next Consultation vs. ‘no intervention’ 
   
England Total 43,016 50,594 7,578  
Per 100,000 100 118 18 
Liverpool Total 829 898 69  
Per 100,000 220 239 18 
Trafford Total 285 361 75  
Per 100,000 164 207 43 
Next Consultation vs. Next Registration 
   
England Total 38,680 45,814 7,134  
Per 100,000 90 107 17 
Liverpool Total 750 810 60  
Per 100,000 199 215 16 
Trafford Total 254 324 70  
Per 100,000 146 186 40 
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9. Main Findings 
9.1 How influential is a lack of knowledge? 
Failing to incorporate any gradients would make a significant impact on the estimated health 
inequality impact (smoking model: +15.89%; alcohol model: -25.08%), which is in line with our 
expectation as detailed in section 3.2. In terms of impact on overall health, ignoring all gradients has 
little impact in the smoking model (-0.21%) and affects to a greater extent the alcohol model (-
5.83%). These results suggest that a complete absence of information about the model inputs which 
are expected to differ by socioeconomic status could still produce reliable estimates of how 
interventions change overall health, but lead to biased estimates on health inequality impact. 
 
Ignoring socioeconomic variation in individual model inputs would affect the estimates on overall 
health and health inequality, and may even change the conclusions about whether the intervention 
reduces/increases health inequality, but there is no clear pattern about which gradient has the 
greatest influence. The extent of inequality in the model input which is ignored (measured using 
concentration index) and the impacts on the amount the intervention is estimated to change overall 
health and health inequality is plotted in Figures 32 and 33. In the smoking model (Figure 32 and 
Figure S15), there is no clear correlation between the concentration index of model input and how 
ignoring inequality in the input affects the estimated results on overall health, but there is a weak 
suggestion of a positive correlation between the concentration index of input and the impact of 
ignoring socioeconomic variation on the estimated intervention impact on health inequality. 
However, such a pattern is not observed in the alcohol model (Figure 33 and Figure S16). 
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Next Registration vs ‘no intervention’  
   
 Impact of ignoring gradients vs. concentration indices in those gradients in alcohol model 
 
Probabilistic sensitivity analysis in the smoking model shows that for the pairwise comparisons 
between each intervention and ‘no intervention’, the variation in overall health impact is mostly 
explained by the quit rate of the intervention and effectiveness, while the variation in uptake also 
explains the variation in health inequality impact. For the comparison between the two 
interventions, which share the same gradients, there is little impact of uncertainty in the gradients 
on uncertainty in estimates of incremental overall health and health inequality. This suggests that 
the lack of information on socioeconomic differences in intervention characteristics would affect the 
decision uncertainty about value for money more than the differences in background parameters, 
behaviour, or behaviour-related health (Figure 17). 
 
9.2 How valuable are modifications to reduce socioeconomic differences? 
Levelling up each model input to the highest level currently achieved in any socioeconomic subgroup 
would drive the impact on health inequality to the direction that favours the intervention, by either 
making the intervention inequality reducing or reducing the extent of inequality, as we would 
expect. It also increases the impact on overall health, so it would not impose a trade-off between 
overall health and inequality, unless the cost of achieving the improvement exceed the benefits. As 
these inputs are potentially modifiable, these results would help to guide the efforts to improve the 
delivery strategies for the health interventions to achieve the optimal impacts on both overall health 
and health inequality. 
 
9.3 How generalisable are conclusions about value for money between settings? 
Generally, the influence of ignoring gradients shows a similar pattern of change across different 
settings. Similarly, the direction of change is the same for levelling up the potentially modifiable 
gradients to the best, which would increase overall health and reduce inequality. 
 
However, there are differences in some of the conclusions between settings. In the smoking 
cessation model, the intervention e-cigarette increases overall health and marginally reduces 
inequality for York, but exacerbates health inequality for England as a whole and in Sheffield. In the 
alcohol model, the magnitude of effects is different when assuming the same population size: 
Trafford is estimated to see a reduction in inequality that is over 2 times greater than the national 
figure, while Liverpool is estimated to see an improvement in overall health that is over 2 times 
greater. Also, in the smoking model, ignoring all gradients would affect the estimated intervention 
impact on overall health to a greater extent at the Local Authority level than at the national level 
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ignoring socioeconomic variation can lead to different qualitative conclusions in different settings, 
e.g., ignoring the gradient in uptake would result in Varenicline being estimated to reduce inequality 
compared to ‘no intervention’ for England and York, but not so for Sheffield. These differences are 
likely driven by the very different deprivation structure of the population (Figure 5 for smoking 
cessation model and Figure 10 for alcohol model). 
 
Furthermore, probabilistic sensitivity analysis in the smoking model shows the different levels of 
uncertainty in the conclusions on overall health and health inequality between settings. For England 
and Sheffield, the intervention increases overall health and reduces inequality with no uncertainty, 
but for York the probability of the intervention being inequality reducing is 37.20% and 55.40%. VOI 
and ANCOVA results demonstrate that the uncertainty/variation in health inequality at the Local 
Authority level is partly explained by the variation in smoking prevalence, while this is not the case at 
the national level. As there is more uncertainty associated with socioeconomic gradients in smoking 
prevalence at Local Authority level than that at the national level, this translates into more variation 
in model outputs. 
 
Although the impact of ignoring socioeconomic differences on the estimates of overall health and 
health inequality is in the same direction between settings, the conclusion about value for money of 
the intervention at one Local Authority would be different compared to other Local Authorities or 
the nation as a whole. Therefore, when making decisions at Local Authority levels, it would be ideal 
to incorporate Local Authority level data to reflect the differences rather than use the data at the 
national level. 
 
9.4 How generalisable are these results between models and disease areas? 
Socioeconomic differences in background parameters, behaviours, behaviour-related health, and 
intervention characteristics are considered in both models. However, the models differ in model 
structure and in the pattern of the socioeconomic gradient assigned to the same input, e.g. the 
opposing gradients in prevalence shown in Figure 12. 
 
Failing to consider gradients entirely, or specific individual gradients, would affect estimates of how 
interventions impact on health inequality and could fundamentally change the conclusions about 
value for money of the interventions. However, there are no clear patterns between models about 
what gradients have what effect and to what extent, which is very context-specific. This may mean 
there is limited scope to triage public health interventions for distributional cost effectiveness 
analysis, as information on inequality in the model inputs does not appear to reliably predict overall 
changes in health inequality. 
 
It is clearly observed that reducing socioeconomic differences in the delivery and effects of 
interventions is unequivocally a good thing, by increasing overall health and reducing health 
inequality, although this might attract additional costs, and further analysis might be needed to 
explore whether the additional costs are worth it. The cost of modifying interventions might vary 
between disease areas even if the benefits of doing so are similar. 
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10.   Conclusions 
Policy makers require information on the distributional impact of potential public health 
interventions, but may lack the resources and time to conduct bespoke distributional cost 
effectiveness analysis in all circumstances. Developing greater understanding of how socioeconomic 
gradients in prevalence, uptake, efficacy, and benefit from treatment interact and translate into 
differential net health inequality impact will be valuable in demonstrating the potential for 
distributional cost effectiveness analysis to add value. 
 
By conducting two case studies, one assessing smoking cessation interventions and the other 
assessing alcohol brief intervention, we found that there is a strong need to consider socioeconomic 
differences in decision models to assess the impact on health inequality of public health 
interventions, otherwise, the conclusions about value for money would be greatly affected. Among 
all the socioeconomic differences defined in both models, the intervention-related differences seem 
to affect the estimates of health inequality most and, therefore, should be considered in future 
evaluations. Furthermore, reducing socioeconomic differences in the delivery and effects of 
interventions has been found to significantly affect the estimates of value for money, by increasing 
overall health and reducing health inequality, although this might attract additional costs and further 
analysis might be needed to explore whether the additional costs are worth it. Finally, the 
conclusions seem different between settings and, therefore, caution should be taken when 
generalising results from national level to Local Authorities, and between Local Authorities differing 
in deprivation structure of the population and other disease- and intervention-related parameters, 
such as prevalence and uptake rate. 
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Appendix 
Table S1. Distribution of NS-SEC groups by IMD quintiles based on HSE datasets 
 
IMD1 (most deprived) IMD2 IMD3 IMD4 IMD5 (least deprived) 
Managerial and professional 18.30% 27.26% 32.24% 40.40% 46.31% 
Intermediate  18.16% 23.48% 25.83% 27.38% 25.21% 
Routine and manual 55.71% 43.46% 38.82% 28.76% 24.75% 
Never worked and long term 
unemployed 
7.83% 5.80% 3.11% 3.46% 3.73% 
 
 
Figure S1. Equity impact plane showing the overall health and health inequality 
 
Table S2. Estimates of incremental NHB and incremental EDE in base-case and scenario analysis 
 
iNHB 
Change in iNHB 
from Base-case 
iEDE 




Change in the impact on 
inequality compared to 
base-case 
e-cigarette vs ‘no intervention’    
Base-case 80,782 - 70,002  -10,780 Increases inequality 
(a) Ignoring all gradients 80,510 -272 (-0.34%) 80,510 10,508 (15.01%) 0 No effect 
(b) Ignoring gradient in:       
  Baseline QALE 80,782 0 (0%) 80,781 10,779 (15.40%) -1 Smaller increase 
  Health opportunity costs 80,782 0 (0%) 69,019 -983 (-1.40%) -11,763 Larger increase 
  Smoking prevalence 85,683 4,902 (6.07%) 69,454 -548 (-0.78%) -16,229 Larger increase 
  Mortality 79,543 -1,239 (-1.53%) 70,261 259 (0.37%) -9,282 Smaller increase 
  Comorbidities 82,418 1,636 (2.03%) 70,853 851 (1.22%) -11,564 Larger increase 
  HRQoL 80,628 -153 (-0.19%) 70,053 51 (0.07%) -10,575 Smaller increase 
  Effectiveness 77,236 -3,546 (-4.39%) 69,942 -60 (-0.09%) -7,294 Smaller increase 
  Uptake 80,436 -345 (-0.43%) 81,463 11,461 (16.37%) 1,027 Inequality-reducing 
(c) Levelling up to the best in:      
  Effectiveness 88,229 7,448 (9.22%) 79,929 9,927 (14.18%) -8,300 Reduce 
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Table S3. Estimates of incremental NHB and incremental EDE in base-case and scenario analysis 
 
iNHB 
Change in iNHB 
from Base-case 
iEDE 




Change in the impact 
on inequality 
compared to base-case 
Varenicline vs e-cigarette     
Base-case 42,968 - 36,551 - -6,417 Increases inequality 
(a) Ignoring all gradients 42,979 11 (0.03%) 42,979 6,428 (17.59%) 0 No effect 
(b) Ignoring gradient in:       
  Baseline QALE 42,968 0 (0%) 42,966 6,415 (17.55%)  -1 Smaller increase  
  Health opportunity costs 42,968 0 (0%) 36,413 -138 (-0.38%) -6,555 Larger increase  
  Smoking prevalence 45,572 2,604 (6.06%) 35,990 -561 (-1.53%) -9,581 Larger increase 
  Mortality 42,277 -690 (-1.61%) 36,730 179 (0.49%) -5,548 Smaller increase  
  Comorbidities 43,895 927 (2.16%) 37,029 478 (1.31%) -6,865 Larger increase 
  HRQoL 42,882 -85 (-0.20%) 36,584 33 (0.09%) -6,298 Smaller increase 
  Effectiveness 41,234 -1,734 (-4.03%) 36,522 -29 (-0.08%) -4,712 Smaller increase 
  Uptake 42,821 -146 (-0.34%) 43,317 6,766 (18.51%) 496 Inequality-reducing  
(c) Levelling up to the best in:      
  Effectiveness 46,608 3,641 (8.47%) 41,404 4,853 (13.28%) -5,204 Reduce  
  Uptake 58,377 15,409 (35.86%) 591,053 22,502 (61.56%) 676 Inequality-reducing 
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Figure S3. Equity impact plane showing scenario analysis results where levelling up to the best 
 
 
Table S4. Overall EVPI and EVPPI of Varenicline vs e-cigarette for England 
 Improvement in overall health  
(incremental NHB>0) 
Improvement in social welfare  
(incremental EDE>0) 
Overall EVPI per person £142,617,861 £94,657,996 
quit rate_Varenicline £116,647,056 £77,425,155 
quit rate_e-cigarette £24,472,449 £17,188,784 
smoking prevalence 0 £7,344 
mortality 0 0 
comorbidities 0 0 
HRQoL £429,714 £390,824 
effectiveness £1,750,667 £1,394,317 
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Overall health (incremental NHB) 
Varenicline vs ‘no intervention’ e-cigarette vs ‘no intervention’ 
  
 
Health-related social welfare (incremental EDE) 
Varenicline vs ‘no intervention’ e-cigarette vs ‘no intervention’ 
  
 
Reduction in health inequality (incremental EDE - incremental NHB) 
Varenicline vs ‘no intervention’ e-cigarette vs ‘no intervention’ 
  
Figure S4. ANCOVA results for England 
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Table S5. Results of base-case and scenario analysis for York 
 
iNHB 
Change in iNHB 
from base-case 
iEDE 




Change in the impact on 
inequality compared to 
base-case 
Varenicline vs ‘no intervention’    
Base-case 659 - 651 - -9 Increases inequality 
(a) Ignoring all gradients 531 -129 (-19.56%) 531 -120 (-18.49%) 0 No effect 
(b) Ignoring gradient in:       
  Baseline QALE 659 0 (0%) 659 9 (1.33%) 0 Smaller increase  
  Health opportunity costs 659 0 (0%) 641 -10 (-1.51%) -18 Larger increase  
  Smoking prevalence 682 23 (3.47%) 643 -8 (-1.19%) -39 Larger increase 
  Mortality 655 -5 (-0.72%) 654 4 (0.54%) 0 Smaller increase  
  Comorbidities 685 25 (3.82%) 673 22 (3.45%) -11 Larger increase 
  HRQoL 656 -3 (-0.51%) 649 -2 (-0.29%) -7 Smaller increase 
  Effectiveness 605 -54 (-8.21%) 607 -44 (-6.81%) 1 Inequality-reducing  
  Uptake 554 -105 (-15.93%) 604 -47 (-7.24%) 49 Inequality-reducing  
(c) Levelling up to the best in:      
  Effectiveness 689 29 (4.45%) 693 42 (6.44%) 4 Inequality-reducing  
  Uptake 756 96 (14.61%) 823 172 (26.46%) 67 Inequality-reducing 
e-cigarette vs ‘no intervention’    
Base-case 431 - 433 - 3 Reduces inequality 
(a) Ignoring all gradients 345 -85 (-19.81%) 345 -88 (-20.32%) 0 No effect 
(b) Ignoring gradient in:       
  Baseline QALE 431 0 (0%) 431 -3 (-0.64%) 0 Inequality-increasing 
  Health opportunity costs 431 0 (0%) 425 -8 (-1.93%) -6 Inequality-increasing  
  Smoking prevalence 446 15 (3.47%) 429 -4 (-0.99%) -16 Inequality-increasing 
  Mortality 428 -3 (-0.70%) 436 2 (0.51%) 8 Larger reduce 
  Comorbidities 447 16 (3.74%) 448 14 (3.31%) 1 Smaller reduce 
  HRQoL 429 -2 (-0.50%) 432 -1 (-0.28%) 4 Larger reduce 
  Effectiveness 394 -36 (-8.45%) 404 -30 (-6.87%) 9 Larger reduce  
  Uptake 362 -69 (-15.93%) 400 -33 (-7.65%) 38 Larger reduce 
(c) Levelling up to the best in:      
  Effectiveness 450 20 (4.58%) 462 28 (6.50%) 11 Larger reduce 
  Uptake 494 63 (14.61%) 546 112 (25.90%) 52 Larger reduce 
Varenicline vs e-cigarette     
Base-case 229 - 217 - -11 Increases inequality 
(a) Ignoring all gradients 185 -44 (-19.08%) 185 -32 (-14.83%) 0 No effect 
(b) Ignoring gradient in:        
  Baseline QALE 229 0 (0%) 229 11 (5.25%) 0 Smaller increase  
  Health opportunity costs 229 0 (0%) 216 -1 (-0.66%) -13 Larger increase  
  Smoking prevalence 237 8 (3.47%) 214 -3 (-1.60%) -23 Larger increase 
  Mortality 227 -2 (-0.74%) 219 1 (0.61%) -8 Smaller increase  
  Comorbidities 238 9 (3.99%) 226 8 (3.74%) -12 Larger increase 
  HRQoL 228 -1 (-0.54%) 217 -1 (-0.31%) -11 Smaller increase 
  Effectiveness 211 -18 (-7.77%) 203 -15 (-6.70%) -8 Smaller increase 
  Uptake 192 -36 (-15.93%) 203 -14 (-6.42%) 11 Inequality-reducing  
(c) Levelling up to the best in:      
  Effectiveness 238 10 (4.21%) 231 14 (6.33%) -7 Smaller increase 
  Uptake 262 33 (14.62%) 277 60 (27.58%) 15 Inequality-reducing 
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Table S6. Results of base-case and scenario analysis for Sheffield 
 
iNHB 
Change in iNHB 
from base-case 
iEDE 




Change in the impact on 
inequality 
compared to base-case 
Varenicline vs ‘no intervention’      
Base-case 2,092 - 1,625 - -467 Increases inequality 
(a) Ignoring all gradients 2,284 192 (9.19%) 2,284 659 (40.58%) 0 No effect 
(b) Ignoring gradient in:       
  Baseline QALE 2,092 0 (0%) 2,092 467 (28.74%) 0 Smaller increase  
  Health opportunity costs 2,092 0 (0%) 1,610 -15 (-0.94%) -482 Larger increase  
  Smoking prevalence 2,188 96 (4.60%) 1,621 -4 (-0.26%) -568 Larger increase 
  Mortality 2,039 -53 (-2.54%) 1,625 0 (0.02%) -414 Smaller increase  
  Comorbidities 2,135 43 (2.04%) 1,640 16 (0.96%) -494 Larger increase 
  HRQoL 2,089 -3 (-0.15%) 1,628 3 (0.20%) -461 Smaller increase 
  Effectiveness 2,052 -40 (-1.92%) 1,703 79 (4.84%) -348 Smaller increase 
  Uptake 2,207 115 (5.49%) 2,102 477 (29.39%) -105 Smaller increase 
(c) Levelling up to the best in:      
  Effectiveness 2,335 243 (11.64%) 1,940 315 (19.40%) -395 Smaller increase 
  Uptake 3,008 917 (43.82%) 2,866 1,241 (76.39%) -143 Smaller increase 
7.2mg e-cigarette vs ‘no intervention’     
Base-case 1,365 - 1,062 - -303 Increases inequality 
(a) Ignoring all gradients 1,490 125 (9.17%) 1,490 428 (40.28%) 0 No effect 
(b) Ignoring gradient in:       
  Baseline QALE 1,365 0 (0%) 1,365 303 (28.49%) 0 Smaller increase  
  Health opportunity costs 1,365 0 (0%) 1,049 -14 (-1.27%) -316 Larger increase  
  Smoking prevalence 1,428 63 (4.61%) 1,061 -1 (-0.08%) -367 Larger increase 
  Mortality 1,331 -34 (-2.50%) 1,062 0 (-0.02%) -269 Smaller increase  
  Comorbidities 1,392 27 (2.00%) 1,072 10 (0.95%) -320 Larger increase 
  HRQoL 1,363 -2 (-0.15%) 1,064 2 (0.18%) -299 Smaller increase 
  Effectiveness 1,338 -27 (-1.98%) 1,115 53 (4.97%) -223 Smaller increase 
  Uptake 1,439 74 (5.43%) 1,364 302 (28.44%) -75 Smaller increase  
(c) Levelling up to the best in:      
  Effectiveness 1,528 163 (11.98%) 1,274 212 (19.94%) -254 Smaller increase 
  Uptake 1,962 597 (43.73%) 1,860 798 (75.09%) -102 Smaller increase 
Varenicline vs 7.2mg e-cigarette      
Base-case 727 - 563 - -164 Increases inequality 
(a) Ignoring all gradients 794 67 (9.23%) 794 232 (41.15%) 0 No effect 
(b) Ignoring gradient in:       
  Baseline QALE 727 0 (0%) 727 164 (29.21%) 0 Smaller increase  
  Health opportunity costs 727 0 (0%) 561 -2 (-0.30%) -166 Larger increase  
  Smoking prevalence 760 33 (4.58%) 559 -3 (-0.60%) -201 Larger increase 
  Mortality 708 -19 (-2.62%) 563 1 (0.10%) -145 Smaller increase  
  Comorbidities 742 15 (2.12%) 568 6 (0.99%) -174 Larger increase 
  HRQoL 726 -1 (-0.15%) 564 1 (0.22%) -162 Smaller increase 
  Effectiveness 714 -13 (-1.81%) 588 26 (4.59%) -125 Smaller increase 
  Uptake 768 41 (5.61%) 738 175 (31.18%) -30 Smaller increase 
(c) Levelling up to the best in:      
  Effectiveness 807 80 (10.99%) 666 104 (18.40%) -141 Smaller increase 
  Uptake 1,047 320 (43.98%) 1,006 443 (78.83%) -41 Smaller increase 
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Figure S9. Equity impact plane showing scenario analysis results for Sheffield where levelling up to the best 
 
Table S7. Overall EVPI and EVPPI of Varenicline vs e-cigarette for York 
 Improvement in overall health  
(incremental NHB>0) 
Improvement in social welfare  
(incremental EDE>0) 
Overall EVPI £750,593 £461,779 
quit rate_Varenicline £535,369 £338,400 
quit rate_e-cigarette £114,783 £75,836 
smoking prevalence 0 0 
mortality 0 £299 
comorbidities 0 00 
HRQoL 0 £215 
effectiveness £1,222 £892 
uptake 0 0 
 
Table S8. Overall EVPI and EVPPI of Varenicline vs e-cigarette for Sheffield 
 Improvement in overall health  
(incremental NHB>0) 
Improvement in social welfare  
(incremental EDE>0) 
Overall EVPI £2,206,030 £1,249,991 
quit rate_Varenicline £1,583,066 £913,999 
quit rate_e-cigarette £259,060 £172,692 
smoking prevalence 0 0 
mortality 0 0 
comorbidities 0 0 
HRQoL 0 £131 
effectiveness 0 0 
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Overall health (incremental NHB) 
Varenicline vs ‘no intervention’ e-cigarette vs ‘no intervention’ 
  
 
Health-related social welfare (incremental EDE) 
Varenicline vs ‘no intervention’ e-cigarette vs ‘no intervention’ 
  
Figure S10. ANCOVA results for York 
 
 
Figure S11. Equity impact plane showing the overall health and health inequality for Sheffield 
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Overall health (incremental NHB) 
Varenicline vs ‘no intervention’ e-cigarette vs ‘no intervention’ 
  
 
Health-related social welfare (incremental EDE) 
Varenicline vs ‘no intervention’ e-cigarette vs ‘no intervention’ 
  
 
Reduction in health inequality (incremental EDE - incremental NHB) 
Varenicline vs ‘no intervention’ e-cigarette vs ‘no intervention’ 
  
Figure S12. ANCOVA results for Sheffield 
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Change in iNHB  
from base-case 
iEDE 





Change in the impact  
on inequality  
compared to base-
case 
Next Consultation vs. Next Registration 
    
Base-case 38,680  45,814  7,134 Reduces inequality 
(a) Ignoring all gradients 41,647 2968 (+7.67%) 40,465 -5349 (-11.68%) -1,182 Increases inequality 
(b) Ignoring gradient in:       
Baseline QALE 38,680 0 (0%) 38,680 -7134 (-15.57%) 0 Increases inequality 
Health opportunity costs 38,680 0 (0%) 46,196 382 (+0.83%) 7,517 Larger reduction 
Drinking prevalence 41,571 2891 (+7.47%) 52,462 6648 (+14.51%) 10,891 Larger reduction 
Mean consumption 39,618 938 (+2.43%) 48,336 2522 (+5.5%) 8,718 Larger reduction 
Peak consumption 42,770 4091 (+10.58%) 52,961 7147 (+15.6%) 10,191 Larger reduction 
Morbidity 40,317 1637 (+4.23%) 42,115 -3699 (-8.07%) 1,799 Smaller reduction 
Mortality 39,639 959 (+2.48%) 43,263 -2551 (-5.57%) 3,624 Smaller reduction 
Screening coverage 41,331 2652 (+6.86%) 49,577 3764 (+8.22%) 8,246 Larger reduction 
Screening positive 40,259 1579 (+4.08%) 50,026 4212 (+9.19%) 9,767 Larger reduction 
(c) Levelling up to the best in:      






10,969 Larger reduction 
Screening rates (global 
optimum) 
43,824 5144 (+13.3%) 53,532 7718 (+16.85%) 9,708 Larger reduction 
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Figure S14. Equity impact plane showing scenario analysis results where levelling up to the best 
 
e-cigarette vs ‘no intervention’  
  
 
Varenicline vs e-cigarette 
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Next Consultation vs ‘no intervention’  
  
 
Next Consultation vs Next Registration 
 
  
Figure S16. Impact of ignoring gradients vs. concentration indices in those gradients in alcohol model 
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